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Sortase A (SrtA) mediated ligation provides a mild and site-specific method for attaching a 
wide range of molecular probes to biological molecules, such as proteins and DNA.    This 
method does not require any toxic reagents or harsh conditions to achieve high level of 
labelling, and the product could be easily isolated from the reaction mixture.    This new 
labelling  techniques  could  potentially  improve  exisiting  technologies  for  studying 
molecular interations.    A number of cloning and protein expression systems for the SrtA 
system were developed  and the  resulting proteins were very stable and in high purity.   
The use of this technique for site-specific protein labelling was investigated.    A range of 
molecules,  such  as  fluorecein  derivitives  and  25  bp  double-stranded  DNA,  were 
successfully ligated to the target proteins in good yield.    The use of the SrtA system in 
protein immobilisation was also thoroughly studied.    A number of proteins with distintly 
different functionalties, such as fluorescent proteins (BFP, EGFP, DsRed), enzyme (Fpr) 
and DNA-binding protein (Tus), were successfully immobilised onto highly cross-linked 
polymeric beads (GMA), soft-polymer resin matrix (Affi-gel) and glass  surfaces.    The 
amount of non-specifically bound protein onto these surfaces was found to be neglectable 
and the activity of the attached protein was retained. 
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Chapter 1:  Introduction 
Staphylococcus aureus (S. aureus) is a gram positive bacterium.    It was first discovered 
by Sir Alexander Ogston from Scotland
1 and can be isolated from over 40% of the human 
population.
2,3    It causes abscesses in many different organ tissues, septicaemia and other 
diseases.    It has a high occurrence of infections and death rate.
4,5    In infants, an infection 
of S. aureus can cause Staphylococcal scalded skin syndrome (SSSS).
6    S. aureus is also 
responsible  for  the  most  common  postsurgical  infections  and  nosocomial  infections.   
Antibiotics such as β-lactam antibiotics (e.g. penicillin) and other anti-bacterial drugs like 
macrolides  and  fluoroquinolones  are  normally  used  for  treating  S.  aureus  infections.
7   
However, under excessive use of antibiotic through out the past years, some strains of S. 
aureus have gained resistance to many, if not all, antibiotics treatments.    Most notable 
antibiotic-resistant  strains  are  Methicillin-resistant  S.  aureus  (MRSA)  and 
Vanomycin-resistant S. Aureus (VRSA, contain a vancomycin resistant gene, VanA) which 
are capable of carrying out normal bacterial functions, such as transpeptidation, even in the 
present of antibiotics.
8    The excessive use of antibiotic treatment has lead to an increase in 
MRSA  infections  in  hospitals  and  other  communities  to  young  adults  and  new  born 
babies.
9-13    Patients infected with such disease even under medical care could be fatal if it 
was not diagnosed early and treated aggressively.
14 
 
In  gram  positive  bacteria,  the  cell  wall  is  generally  composed  of  a  primary  polymer, 
peptidoglycan, and a secondary polymer, such as proteins and carbohydrates immobilised 
in the peptidoglycan structure.    In S. aureus, the most common surface protein is protein 
A,  an  immunoglobulin-binding  protein,
15,16  which  is  covalently  attached  to  the 
pentaglycine on a cell wall precursor, lipid II.    Once lipid II is incorporated into the cell Introduction 
2 
 
wall, surface proteins are available to interact with the cell surface of host tissues and cause 
infections.
17    The covalent attachment of surface proteins to pentaglycine of lipid II is 
catalysed by sortase A (SrtA).    It has been demonstrated that in the absence of SrtA gene 
(srtA) S. aureus failed to anchor surface proteins to the cell wall precursor and as a result 
reduced infectivity to the host cell dramatically.
18    This finding made SrtA a potential 
drug target for future anti-bacterial drug developments.     
1.1)    Sortase 
Sortase, a transpeptidase, is a bacterial enzyme found in a wide range of gram-positive 
bacteria.    It  is  responsible  for  the  covalent  attachment  of  bacterial  surface  proteins  to 
peptidoglycan of the cell wall in bacteria.    There are four main classes of sortase, namely 
class A, B, C and D.
19    Different bacterias have different numbers and types of sortases.   
For example, S. aureus has four different sortases, with SrtA and SrtB the most important 
ones;
20 S. pneumoniae has up to four different sortases
21 and Corynebacterium effciens up 
to  ten.
22    Each  class  recognises  different  amino  acid  sequences  of  the  motif.    SrtA 
recognises  LPXTG,  where  X  can  be  any  amino  acid.    SrtB  recognises  the  C-terminal 
NPQTN motif; SrtC the  LPNTA motif and SrtD recognises  LPXTG  motif in the pilin 
protein (BcpA) precursor.
23-27     
 
The structure of S. aureus SrtA has recently been solved by nuclear magnetic resonance 
(NMR) spectroscopy (Figure 1.1 ).    The enzyme has a unique β-barrel structure  with 
eight β-strands aligned in an antiparallel and parallel fashion.








Figure 1.2 NMR structure of the catalytic pocket of S. aurues SrtA showing the side chain 
of His-120 and Cys-184 at the active site.
28 
 
At the active site the Cys-184 and His-120 ion pair
28,29 is located in the catalytic pocket 
which  is  formed  by  the  residues  in  the  loops  at  one  end  of  the  β-barrel  (Figure  1.2).   
Cys-184  is  activated  by  the  imidazole  ring  of  His-120
28,30  for  mediating  the Introduction 
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transpeptidation.    It was found that in the present of Ca
2+ the activity of SrtA increased.
28   
Some  suggested  that  the  increase  in  enzymatic  activity  was  due  to  modulation  of  the 
structure and dynamics of the active site loop by the cation.
31 
1.2)    The action of SrtA in bacteria 
At the N- terminus, a signal peptide directs the surface proteins to the secretory pathway on 
the cytoplasmic membrane.    The signal peptide is then cleaved by signal peptidase after 
translocation of the surface protein across the cytoplasmic membrane.    At the C-terminus 




An LPXTG motif (Leucine, Proline, X, Threonine and Glycine. X: any amino acid) 
A hydrophobic region 
A tail of charged residues 
 
 
Figure  1.3  The  secreted  protein.    The  signal  peptide  directs  the  immatured-protein 
through the secretory pathway. The hydrophobic region and the charged residue lock the 
protein in position in the membrane.     
The hydrophobic region and the charged residues help to position the protein substrate in Lilyan Chan 
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Figure 1.4 The SrtA-mediated cell surface protein anchoring.    The signal peptide directs 
the target protein through the secretory pathway where the hydrophobic region and the 
charged  residue  hold  the  protein  in  position  in  the  membrane.    Afterwhich  the  signal 
peptide is cleaved by signal peptidase.    SrtA recognises the LPXTG motif of the target 
protein and catalyses the tranpeptidation.    Once the surface protein is incorporates with 
the cell wall precursor, the precursor is polymerisaed into a matured peptidoglycan.   
 
Once the protein is held in position in the membrane, the sulfhydryl group of Cys-184 in 
SrtA carries out a nucleophilic attack on the amide bond between threonine and glycine of 
the LPXTG motif to form a thioester bond.    The amine group of the pentaglycine unit of 
Lipid II then acts as a nucleophile, attacking the carbonyl group of thioester formed by 
SrtA to form an amide bond.
35-37 
































































































































































































































































Figure 1.5 Schematic diagram of the SrtA-mediated transpeptidation. 
Once the surface protein is covalently attached to lipid II, the precursor is polymerised into 
matured peptidoglycan and forms the bacterial cell wall
38-40 with covalently incorporated 
proteins on the surface.
41     
 
The  mechanism  of  SrtA  catalysed  transpeptidation  has  been  studied  using  a  synthetic 
substrate Abz-LPXTG-Dap(Dnp)-OH by fluorescence measurement.    In the presence of 
the  fluorophore–quencher  (Abz-Dnp  pair)  labelled  LPXTG  motif  and  a  pentaglycine 
substrate, SrtA cleaved the amide bond between threonine and glycine of the LPXTG motif, 
removing the quencher from the synthetic substrate and covalently links threonine to the 
pentaglycine forming Abz-LPXTGGGGG-OH and NH2-G-Dap(Dnp)-OH (Figure 1.6).     
 
 
Figure 1.6 Schematic diagram of the SrtA substrate analysis. 
 
As the Abz and Dnp pair were no longer in close proximity in the product, the emitted 
fluorescence  by  Abz  was  not  quenched  by  Dnp.    This  in  theory  allows  detection  and 

















Amide bond formed between the 
carboxyl group of the T and amine 






practice the fluorophore attached to the LPXTG motif self-quenched at moderaetly high 
concentration and therefore affecting the measurement for kinetic analysis.    An improved 
method which measured the formation of product by HPLC based on UV/Vis absorbance 
or fluorescence was used.
42    By using the this method, the estimated Km and Kcat for SrtA 
using tetraglycine as substrate were determined to be 5.5 mM and 0.270 s
-1 repectively, 
which is relatively fast.
42    The kinetic mechanism of different substrates has been studied 
using the same methodology.
35 
1.3)    Sortase A inhibition 
Sortase plays an important role in anchoring different surface proteins onto the cell wall 
precursor.    In  S.  aureus,  mutants  that  cannot  express  SrtA  have  shown  dramatically 
reduced infectivity to the host cells.
17    There is a growing interest to inhibit SrtA and 
other similar proteins in the hope of treating bacterial infections, such as MRSA and VRSA, 
using  novel  anti-bacterial  drugs.    The  chemical  that  inhibits  sortase,  which  in  turn 
prevents  the  cell  wall  anchoring  reaction,  was  found  even  before  the  identification  of 
sortase.
43    While  later,  Vancomycin  and  Moenomycin  were  also  found  to  reduce  the 
amount of surface proteins being anchored onto the cell wall precursor,
43 and compounds 
including  sulfhydryl  group,  such  as  organomercurials  and  methanethiosulfonates,  also 
show inhibitory of the surface protein anchoring reaction.     
 
Not only synthetic compounds have been tested for the inhibition of SrtA, natural products 
extracted  from  plants  and  marine  invertebrate  also  found  to  inhibit  the  enzyme.   
Compounds from eighty medicinal plants from Korea were tested for the inhibitory effects 
on  sortase.
41    A  specific  compound,  β-sitosterol-3-O-glucopyranoside,  isolated  from 




44    Another example of natural compounds with inhibitory effect on sortase 
was  Isoquinoline  alkaloids,  isolated  from  the  rhizomes  of  Coptis  chinensis.    It  was 
determined to have an IC50 of 8.7  g/mL.
45    Extracts of a marine invertebrate, Topsentai 
genitrix, which is known to have antimicrobial activity was also tested for the inhibition of 
sortase.    A compound was found in the extract, identified as bis(indole) alkaloids with an 
IC50 of ~15  g/mL.
46   
 
 
1.4)    Protein microarrays 
With its unique property in catalysing specific  substitution reactions, sortase has many 
potential  applications,  such  as  in  biological  molecule  labelling  and  site-specific 
immobilisation.    These will be discussed in more details in Chapter 3 and 4. 
 
One  of  the  promising  technology  to  study  protein–molecule  interaction  is  protein 
microarrays.    It  has  been  demonstrated  in  a  wide  range  of  fields,  in  vitro  diagnostic 
immunoassays and drug discovery.    This method was first demonstrated by MacBeath et 
al.  in  2000,
63  where  the  methodology  was  “borrowed”  from  then  exisiting  DNA 
microarrays.    In this demonstration, proteins, such as BSA and protein G, were spotted 
directly  on  to  aldehyde-functionalised  glass-slide  using  a  commercially  available  DNA 
arrayer.    The  immobilised  proteins  showed  some  degree  of  functionality.    Modified 
methodologies were developed to immobilise different proteins.    For instance, in another 
example, glass slides coated with avidin were used to capture biotinylated protein probes, 
namely EGFP, MBP and GST.
47,48    Afterwhich, the slide was immersed in a solution of 
Cy3-labelled glutathione, a ligand for GST.
47,49    The result showed that only area spotted Lilyan Chan 
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with GST reacted with the Cy3-labelled substrate, whereas other areas had little reactions.     
 
 
Figure  1.7  The  protein  probes  were  spotted  onto  the  avidin  plate  after  which  a 
Cy3-labelled substrate for GST was added.    Only the area spotted with GST reacted with 
the substrate. 
This  powerful  technique  provides  many  solutions  to  the  ever  growing  protein  analysis 
problems.    The glass slides can accommodate an ultra-high density of proteins, each with 
nanoliter volume.    With the on-going development of automated instrumentations, a high 
number of protein-based analysis could be carried out in a highly parallel manner. 
1.5)    Suspension Arrays 
Three-dimentional  micron-sized  solid  supports  have  many  applications,  such  as 
chromatography  and  biological  assays  in  suspension  arrays.    One  application  is  the 
purification of nuclear proteins that binds to cisplatin (cis-diamminedichloroplatinum (II), 
CDDP),
50 a chemotherapy agent, which is used to treat different kinds of caner.    At the 
point of contact between the CDDP and DNA molecule , it causes the DNA to unwind and 
bend.    The CDDP binds to the cancer cell DNA and causes different effects, including 
phosphorylation  of  tumor  suppressor  protein  p53,  which  causes  apoptosis
51  and  DNA 
repair.
52    The protein was being purified using affinity chromatography on cellulose, but Introduction 
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the efficiency was very low as it was hard to make the protein to bind to the column.
53     
Noval submicron-sized latex beads were synthesised from the co-polymerisation of styrene 
and GMA in soap free aqueous solution




Figure  1.8  The  pathway  of  the  CDDP-DNA  binding  protein  purification.    The 
CDDP-DNA-bead was loaded into the protein solution, the CDDP-DNA binding protein or 
proteins that recognise the CDDP-damaged DNA will attach to the beads.    The beads 
were washed with buffer and washed with elution buffer to elute the protein out from the 
beads.     
The  beads  were  then  incubated  in  the  protein  solution  for  the  attachment  of  specific 
proteins  that  interact  with  CDDP-DNA  complex  or  CDDP-damaged  DNA.    The 
purification affinity of the CDDP-DNA-beads has a higher level of protein purified than 
the DNA-beads.    The immobolisation of proteins onto surfaces has been done by using 
reactive groups, such as carboxyl-, amino- or sulfide groups on the protein and covalently 
linked to appropriate functional groups on the solid surface.
55     
 
However,  the  lack  of  specificity  results  in  proteins  attached  on  the  surface  in  random 
orientation.    As a result, the protein probe might not retain its activity and substrates may   
not  be  able  to  access  to  the  binding  site.    In  addition,  the  protein  solution  has  to  be 
extremely pure in order to prevent contamination during the coupling reaction.    These Lilyan Chan 
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disadvantages could potentially be solved by affinity binding where a synthetic tag on the 
protein  probe  is  captured  by  its  counterpart  on  the  suface.
56    Examples  include  the 
His-tag/Ni-affinity system and protein A/G for immunoglobulin capturing.
57,58     
 
We would like to use the SrtA to provide a new, mild and site-specific method for labelling 
biological  molecules  such  as  proteins  or  DNA.    In  addition,  we  would  hope  to  use 
SrtA-mediated  ligation  for  immobilising  proteins  onto  a  range  of  solid  supports  and 
surfaces.
59-62 
1.6)    Aim of this project 
In  this  project,  we  aimed  to  develop  novel  applications  of  SrtA.    In  particular,  new 
methodologies  for  in  vitro  labelling  of  biological  molecules  and  novel  protein 
immobilisation techniques. 
 
To  this  end,  we  wanted  to  clone,  express  and  purify  a  number  of  proteins,  such  as 
His6-SrtA, BFP-, EGFP-, DsRed- and Fpr-LPETGG-His6 proteins.    These proteins would 
then be used for a number of experiments to demonstrate the SrtA-mediated reactions. 
 
For protein immobilisation, we also wanted to study the functionality of the immobilised 
protein probe molecules.     
   Introduction 
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Chapter 2:  Production of proteins 
2.1)    Introduction 
Sortase-mediated  ligation
1, 2  could  potentially  provide  an  improved  method  for  protein 
immobilisation.    There  are  three  major  methods  for  attaching  biological  molecules  on 
surfaces:  1)  passive  adsorption;  2)  affinity  binding  and  3)  covalent  linkage.    The 
attachment of protein molecules on surfaces by these methods are either non-permanent or 
in random oreientation.    These undesired properties have great impacts on reducing the 
activity of the immobilised proteins.    Instead of directing the protein molecules to bind to 
the surface, porous gel matrix can be formed around the protein molecules, providing a 
gentle  approach  for  trapping  biological  molecules  and  preserving  the  delicate  protein 
three-dimentional  structures.
3-5    The  immobilisation  of  proteins  onto  surfaces  will  be 
further discussed in chapter 4. 
 
For protein labelling, most methods involve the formation of covalent linkage between the 
target  protein  and  the  label.    Most  commercially  available  fluorescent  dyes  are 
pre-functionalised  with  reactive  functional  groups,  such  as  aldehyde,  NHS-ester  and 
isothiocyanate, to simplify the attachment process.    These functional groups reacts with 
any available free amines of the protein surface and so the reactionis non site-specific and 
highly  uncontrollable.    Another  method  called  intein-mediated  ligation  which  provides 
site-specific ligation to the target protein.    In this method, a target protein is “activated” 
by expressing with intein (~50 kDa) as a fusion protein.    The thioester linkage between 
the two proteins can be nucleopililly attacked by thio-containing compound, replacing the Lilyan Chan 
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intein portion.    However, according to the three-dimentional structure of the target protein, 
the  expression  of  the  target-intein  fusion  could  be  difficult.      The  thioester  linkage 
between the two protins can be easily hydrolysed in vivo, resulting in immature cleavage.
5   
 
Unlike  intein,  sortase-mediated  ligation  does  not  activate  the  target  protein  unless  the 
enzyme is present in the reaction.    This prevents immature cleavage by hydrolysis during 
storage.    The environment for protein ligation with sortase is mild (50 mM Tris, 100 mM 
NaCl, 5 mM CaCl2, pH 7.5),
6 which is suitable for most proteins. 
 
We  were  interested  in  using  the  SrtA-mediated  ligation  for  1)  labelling  biological 
molecules  for  visualising  molecular  interactions  and  2)  attaching  proteins  onto  solid 
surfaces for functional analysis.    To this end, we selected a range of functionally different 
proteins  for  the  labelling  and  attachment  experiments  (see  Chapter  3  and  4  for  more 
details). 
2.1.1)    Fluorescent proteins 
Fluorescent proteins are extremely useful as biomolecular tags for visualising biological 
interactions in both in vitro and in vivo studies.    The most well-known fluorescent protein 
is Green fluorescent protein (GFP) which is isolated from the jellyfish Aequorea Victoria.
7   
Figure 2.1 shows the crystal structure on a monomeric GFP molecule.    It has a β-barrel 
structure  (Figure  2.1)  with  the  matured  chromophore  situated  inside  the  barrel.  The 
chromophore is formed in situ using three internal amino acid residues of the peptide chain: 
Ser-65, Tyr-66 and Gly-67 (Figure 2.1)
8-10    Matured GFP shows maximum excitation and 
emission wavelengths of 488 nm and 509 nm repectively. 




Figure 2.1 Crystal structure of monomeric GFP with the matured chromophore situated 
inside the β-barrel.   
 
Many other fluorescent proteins routinely used in biological assays are mutants of GFP.
8-11 
For example, Blue Fluorescent Protein (BFP) is mutated from GFP by substituting Tyr-66 
with His-66.
10, 12-14    This changes the fluorescence properties of the matured chromophore 
where the excitation emission wavelength are shifted to 382 nm and 459 nm resepectively.   
   





Figure 2.2 Biosynthesis of the matured GFP chromophore. 
 
Other  fluorescent  proteins,  such  as  Yellow  Fluorescent  Protein  (YFP)  and  Cyan 
Fluorescent Protein (CFP) are prepared by a similar method.    Another natural fluorescent 
protein,  DsRed,  is  isolated  from  Discosoma  sp.
15-17    The  amino  acid  sequence  of  this 
protein is very different from GFP but they are structurally very similar.    The maximum 
excitation and emission wavelengths are 545 nm and 620 nm respectively. 
 
Dur to their excellent fluorescence properties, fluorescent proteins are extensively used in 
molecular biology for visualising molecular interactions.    They can be easily incorporated 
at the N- or C-terminus of the target protein by genetic engineering and express as a fusion 
protein. 
   Production of proteins 
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2.1.2)    Tus 
Tus  is  a  DNA-binding  protein  that  forms  a  complex  with  the  chromosomal  ter  DNA 
sequence and inhibit the progression of the DNA replication fork.
18    It also inhibits the 
DNA replication of plasmid R6K.
19, 20    The binding of Tus to several ter sites was shown 
by  footprinting  with  copper-phenanthroline,
21  DNase  I,
22,23  and  hydroxyl  radicals.
24,25   
Tus binds to the terB site with an equilibrium dissociation constant (Kd) of 3.4 X 10
-13 M 
and a dissociation half-life of about 550 min at pH 7.5 in vitro.
24    Its binding to R6K 
terR2  under  the  same  conditions  was  weaker  due  to  a  higher  dissociation  rate.
24   
Interesingly, Tus bind to terB as a monomer, which is unusual for a DNA-binding protein 
but this is consistent with the asymmetry of the ter sites and replication fork arrest.
26    We 
were interested in immobilising this DNA-binding protein to solid supports using the SrtA 
system and studying the protein activity after the attachment.    This will be discussed in 
more details in Chapter 4. 
2.1.3)    Flavodoxin reductase 
Flavodoxin (ferredoxin) reductase is found in E. coli
27-31 and is responsible for transporting 
electrons between flavodoxin and NADPH.
30, 32    It is involved in the reductive activation 
of pyruvate formate lyase,
33 cobalamin-independent methionine synthase,
34 and anaerobic 
ribonucleotide  reductase.
35  It  also  protects  against  superoxide  radicals  due  to  methyl 
viologen  in  the  presence  of  oxygen.
31    In  order  to  understand  the  enzymatic  activity, 
Wood et al. attempted to label Fpr with fluorescein derivities using the intein labelling 
system.    The first step was to express Fpr-intein fusion protein.    Unfortuately, the fusion 
protein  was  found  to  be  unstable  and  the  linkage  between  Fpr  and  the  intein  was 
hydrolysed.
5    We were interested to access the possibility of labelling such challenging 
protein with the novel SrtA system.    This will be discussed in more details in Chapter 3. Lilyan Chan 
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2.2)    Plasmid construction 
For SrtA to recongise the target protein for labelling reactions, a LPETGG tag was added 
to the C-terminus of the protein, followed by a His6 tag to assits protein purification by 
Ni-affinity  chromatography.  For  the  convenience  for  future  plasmid  constructions, 
restriction site NdeI was situated before the target gene, and XhoI was inserted by PCR 
between the target gene and LPETGG-His6 tag.    The target gene can be replaced by any 
desired gene to express different proteins tagged with LPETGG-His6. For example, the 
plasmid  pLLC066  (BFP-LPETGG-His6)  was  constructed  by  introducing  LPETGG-His6 




Figure 2.3 Construct design for the expression of LPETGG-His6 tagged proteins. 
   
NdeI EcoRI XhoI
XhoI EcoRI
CTC GAG TTA CCG GAA ACT GGT GGC CAC CAT CAC CAT CAC CAT TGA  ATTC 
Leu Glu Leu Pro Glu Thr Gly Gly His His His His His His Stop
Target gene LPETGG His6
NdeI EcoRI XhoI
XhoI EcoRI
CTC GAG TTA CCG GAA ACT GGT GGC CAC CAT CAC CAT CAC CAT TGA  ATTC 
Leu Glu Leu Pro Glu Thr Gly Gly His His His His His His Stop
Target gene LPETGG His6
NdeI EcoRI XhoI
XhoI EcoRI
CTC GAG TTA CCG GAA ACT GGT GGC CAC CAT CAC CAT CAC CAT TGA  ATTC 
Leu Glu Leu Pro Glu Thr Gly Gly His His His His His His Stop
XhoI EcoRI
CTC GAG TTA CCG GAA ACT GGT GGC CAC CAT CAC CAT CAC CAT TGA  ATTC 
Leu Glu Leu Pro Glu Thr Gly Gly His His His His His His Stop
XhoI EcoRI
CTC GAG TTA CCG GAA ACT GGT GGC CAC CAT CAC CAT CAC CAT TGA  ATTC 
Leu Glu Leu Pro Glu Thr Gly Gly His His His His His His Stop
Target gene LPETGG His6 
2.3)    Results 
2.3.1)    Amplification and subcloning of 
The gene srtA was amplified by PCR from 
with primers SrtAf and 
protein.    The PCR product was
purified.    The  purified 
(SOT012)  forming  pLLC064.    Plasmid  was  transformed  into 
competent cells (Clontech
the  desired  plasmid  isolated  using  commercially  available  miniprep  kit  accordin
manufacturor’s  instruction
digested by NdeI and 
From  the  1%  agarose  gel  shown  below
NdeI-EcoRI fragments
bp), srtA (555 bp) and the plasmid backbone 
 
 
Figure 2.4 Gel electrophoreisis analysis of the 
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 and Discussion 
2.3.1)    Amplification and subcloning of srtA 
was amplified by PCR from S. aureus subsp. genomic DNA 
f and SrtAb (section 2.5.1) which inserted a His6
protein.    The PCR product was digested with NdeI and EcoRI for analysis
purified.    The  purified  his6-srtA  gene  was  inserted  into  pETMCSIII
forming  pLLC064.    Plasmid  was  transformed  into 
(Clontech, CA, USA).    Ampicillin-resistant colonies were selected and 
plasmid  isolated  using  commercially  available  miniprep  kit  accordin
manufacturor’s  instruction  (Promega,  Southampton,  U.K.).    The  purified  plasmid  was 
I and EcoRI restriction enzymes and then analysed by gel electrophoresis
From  the  1%  agarose  gel  shown  below  (Figure  2.4)  the  linearlised  plasmid  and  the 
fragments were in agreement with the theoretical value of the plasmid
and the plasmid backbone (4666 bp).  
 
Gel electrophoreisis analysis of the pLLC064.    1% agarose gel was stained 
Production of proteins 
genomic DNA (ATCC 35556) 
6 tag at the C-terminus of 
for analysis and then gel 
gene  was  inserted  into  pETMCSIII  subcloning  vector 
forming  pLLC064.    Plasmid  was  transformed  into  E.  coli  XL-1  Blue 
colonies were selected and 
plasmid  isolated  using  commercially  available  miniprep  kit  according  to 
).    The  purified  plasmid  was 
sed by gel electrophoresis.   
the  linearlised  plasmid  and  the 
were in agreement with the theoretical value of the plasmid (5221 
.    1% agarose gel was stained Lilyan Chan 
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with ethidium bromide.    Lane 1: DNA marker; lane 2: plasmid with no digestion; lane 3: 
plasmid linearlised with NdeI; lane 4: plasmid digested with NdeI and EcoRI. 
 
2.3.2)    Amplification and subcloning of bfp-lpetgg-his6 
The gene bfp-lpetgg-his6 was amplified from pKLC065 by PCR using primers Lc01 and 
SOT015 (section 2.5.1).    The purified PCR product was digested with NdeI and EcoRI 
and then gel purified.    Similarly, pETMCSI was digested with NdeI and EcoRI and the 
plasmid  backbone  was  gel  purified.    The  bfp-lpetgg-his6  gene  was  inserted  into  the 
pETMCSI  backbone  forming  pLLC066.    Plasmid  was  transformed  into  XL-1  Blue 
competent  cells  for  replication.    Ampicilin-resistant  colonies  were  selected  and  the 
plasmid extracted by miniprep.    The extracted plasmid was digested by NdeI and XhoI 
restriction enzymes and then analysed by gel electrophoresis.    The linearlised plasmid and 
the NdeI-XhoI fragments were in agreement with the theorectical value of the plasmid 
(5415 bp), bfp-lpetgg-his6 (771 bp) and the plasmid backbone (4644 bp). 






Figure 2.5 Gel enectrophoresis analysis of pLLC066.    1% agarose gel was stained with 
ethidium bromide. Lane 1: DNA marker; lane 2: plasmid with no digestion; lane 3: plasmid 
linearlised with NdeI; lane 4: plasmid digested with NdeI and XhoI. 
2.3.3)    Amplification and subcloning of egfp-lpetgg-his6 
The  construction  of  pLLC146  (egfp-lpetgg-his6)  was  different  from  pLLC066 
(bfp-lpetgg-his6).    The gene egfp was extracted from pJS110 (provided by Joseph She) by 
digestion with NdeI and XhoI restriction enzymes and then gel purified.    The backbone 
was obtained by digesting pLLC066 with NdeI and XhoI restriction enzymes.    The gene 
was inserted inframe to the backbone to form pLLC146.    The plasmid was transformed 
into E. coli XL-1 Blue and extracted using a miniprep kit as descriped previously.    The 
extracted plasmid was digested by NdeI and XhoI restriction enzymes and then analysed by 
gel  electrophoresis.    The  linearlised  plasmid  and  the  NdeI-XhoI  fragments  were  in 
agreement with the theorectical value of the plasmid (5415 bp), egfp-lpetgg-his6 (771 bp) 
and the plasmid backbone (4644 bp). 





Figure 2.6 Gel electrophoresis analysis of pLLC146.    1% agarose gel was stained with 
ethidium bromide. Lane 1: DNA marker; lane 2: plasmid with no digestion; lane 3: plasmid 
linearlised with NdeI; lane 4: plasmid digested with NdeI and XhoI.   
2.3.4)    Amplification and subcloning of dsred-lpetgg-his6 
The construction of pLLC152 (DsRed-LPETGG-His6) plasmid was similar to pLLC146.   
The dsred gene was extracted from pJS120 (provoded by Joseph She) by digestion with 
NdeI and XhoI restriction enzymes and then gel purified.    The backbone was obtained by 
digesting pLLC066 with NdeI and XhoI restriction enzymes.    The purified dsred gene was 
ligated  to  the  backbone  containing  LPETGG-His6  to  form  pLLC152  in  pETMCSI 
subcloning vector.    The plasmid was transformed into E. coli XL-1 Blue and extracted 
using  miniprep.    The  extracted  plasmid  was  redigested  by  different  sets  of  restriction 
enzymes and analysed by 1% agarose gel to check the correct plasmid was formed. 





Figure 2.7 Gel electrophoresis analysis of pLLC152.    1% agarose gel was stained with 
ethidium  bromide.    Lane  1:  DNA  marker;  lane  2:  plasmid  with  no  digestion;  lane  3: 
plasmid linearlised with NdeI; lane 4: plasmid digested with NdeI and XhoI. 
2.3.5) Amplification and subcloning of fpr-lpetgg-his6 
The  construction  of  pLLC155  (fpr-lpetgg-his6)  plasmid  was  different  from  the  others.   
Since there was a natural NdeI site situated witin the fpr gene, a PciI site was introduced at 
the 5’ end of the gene instead. fpr was extracted from pRJW/2960/88 by digestion with 
PciI  and  XhoI  and  then  gel  purified.    The  pBAD  vector  backbone  was  obtained  by 
digesting  pLLC066  with  the  same  set  of  restriction  enzymes.    The  purified  fpr  was 
inserted into the backbone containing the lpetff-his6 tag to form pLLC155.    The plasmid 
was transformed into XL-1  Blue competent cells and the desired plasmid extracted by 
miniprep as decribed above.    The extracted plasmid was digested by two different sets of 
restriction enzymes, set 1: NdeI, and produced two fragments with 2300 bp and 2683 bp 
respectively; set 2: PciI and NcoI restriction enzymes and produced two fragments with 
1756 bp and 3227 bp respectively.    The redigestion was analysed by gel electrophoresis 





Figure 2.8 Gel electrophoresis analysis of pLLC155.    1% agarose gel was stained with 
ethidium bromide.    Lane 1: DNA marker, lane 2: set 1 of redigestion, lane 3: set 2 of 
redigestion. 
2.3.6)    Protein expression studies 
For  the  BFP-,  EGFP-,  DsRed-,  Fpr-LPETGG-His6  and  His6-SrtA  proteins,  the 
corresponding plasmids were individually transformed into E coli. BL21(DE3) competent 
cells to express the desired proteins. 
 
A small scale expression study was carried out and the expressed proteins were purified 
using a small Ni-affinity column.    In this purification method, proteins with a His6 tag 
were complexed strongly to the immobilised Ni
2+ cations on the resin.    Most of the other 
proteins were washed away from the column during the washing step.    After which, the 
proteins  were  eluted  with  eluting  buffer  containing  low  (50  mM)  or  high  (500  mM) 
concentration on imidazole.    Proteins non-specifcally bound to the resin were eluted in 
the  presence  of  low  concentration  of  imidazole,  while  desired  proteins  were  eluted  at 




2.3.7)    Expression of His6-SrtA 
The plasmid containing the his6-srtA sequence (pLLC064) was transformed into E. coli 
strain  BL21(DE3)  and  then  plated  onto  a  LB-argar  gel  supplemented  with  ampicillin. 
Antibiotic-resistant colonies were selected to inoculate 100 mL of LB medium overnight.   
After overnight incubation, 1 mL of the overnight culture was transferred to 100 mL of 
sterile LB medium and incubated at 37 ℃ until the OD600 reach ~0.6.    The culture was 
then induced with 0.1% w/v of IPTG for expressing the desired proteins for a further 3 
hours at 37 ℃.    The cells were pelleted by centrifugation and the supernatant discarded.   
The pellet was resuspended in lysing buffer and treated with lysozyme and sonication.   
The desired protein was purified from the clear lysate using a Ni-affinity spin column.   
The flow through, wash through and elution samples were analysed by 15% SDS-PAGE 
gel stained with Coomassie blue (Figure 2.9).    According to the gel, a strong band at ~30 
kDa  was  observed  in  the  elution  samples,  which  is  higher  than  the  expected  value  of 
His6-SrtA (~21 kDa).    In order to confirm the identy of this protein, a plasmid with a 
similar construct (a gift from Prof. Bailey) was transformed into E. coli strain BL21(DE3) 
and the clear lysate from the two expressions were compared.    The standard His6-SrtA 
also appears to have a higher molecular weight at ~30 kDa.      This phenomenon might be 
due  to  incomplete  unfolding  of  the  protein  during  gel  electrophoresis.    A  large  scale 
expression (5 L) and purification of this protein was carried out using pLLC064.    The 
purified protein was stored at -80 ℃ for future use. 





Figure 2.9 SDS-PAGE  analysis of the expressed His6-SrtA.    15% acrylamide gel was 
stained with Coomassie blue.    Lane 1: molecular weight marker; lane 2: whole cell from 
SrtA expression in BL21(DE3), lane 3: cell pellet from SrtA expression in BL21(DE3). 
2.3.8)    Expression of BFP-LPETGG-His6 
The plasmid containing the bfp-lpetgg-his6 sequence (pLLC066) was transformed into E. 
coli strain BL21(DE3) and the BFP-LPETGG-His6 protein was expressed and purified by 
Ni-NTA  affinity  chromatography  (50  mL).  The  supernatant  and  cell  pellet  from  the 
expression were analysed by 15% SDS-PAGE gel with Coomassie blue staining (Figure 
2.10).    The purified protein was excited by UV light and the resulting fluorescence was 
observed  visually.    From  the  gel,  a  strong  band  ~29  kDa  coorespond  to 
BFP-LPETGG-His6  was  found.    A  large  scale  expression  (5  L)  and  purification  of 
BFP-LPETGG-His6 protein was carried out and the purified fluorescent protein was stored 
at -80 ℃ for future use.   
 
 





Figure  2.10  SDS-PAGE  analysis  of  the  expressed  BFP-LPETGG-His6.    15%  gel  was 
stained with Coomassie blue. Lane 1: molecular weight marker, lane 2: supernatant from 
expression in BL21(DE3), lane 3: cell pellet from expression in BL21(DE3). 
2.3.9)    Expression of EGFP-LPETGG-His6 
The plasmid containing the egfp-lpetgg-his6 sequence (pLLC146) was transformed into E. 
coli strain BL21(DE3) and the resulting EGFP-LPETGG-His6 protein was expressed and 
purified by Ni-affinity chromatography as decibed above.    The supernatant and cell pellet 
were  analysed  by  15%  SDS-PAGE  with  Coomassie  blue  staining  (Figure  2.11).    The 
purified protein was exicited by UV and the fluorescence was observed visually.    A strong 
band  ~29  kDa  corresponding  to  the  desired  protein  was  observed.    A  large  scale 
expression (5 L) and purification were carried out and the purified fluorescent protein at 
-80 ℃ for future use.   
 





Figure 2.11 SDS-PAGE analysis of the expressed EGFP-LPETGG-His6.    15% gel was 
stained with Coomassie blue. Lane 1: molecular weight marker, lane 2: supernatant from 
expression in BL21(DE3), lane 3: cell pellet from expression in BL21(DE3). 
2.3.10)    Expression of DsRed-LPETGG-His6 
The plasmid containing the dsred-lpetgg-his6 sequence (pLLC152) was transformed into E. 
coli strain BL21(DE3) and the resulting DsRed-LPETGG-His6 was expressed and purified 
by  Ni-affinity  chromatography  as  described  above.    The  supermatamt  amd  cell  pellet 
were  analysed  by  15%  SDS-PAGE  gel  stained  with  Coomassie  blue  (Figure  2.12).   
Unlike BFP and EGFP, the red fluorescence was observed visually under laboratory white 
light.    A strong band ~29 kDa corresponding to the desired protein was observed.    A 
large scale expression (5 L) and purification were carried out and the purified fluorescent 
protein was stored at -80 ℃ for future use. 
EGFP-LPETGG-His6 





Figure 2.12 SDS-PAGE analysis of the expressed EGFP-LPETGG-His6.    15% gel was 
stained with Coomassie blue. Lane 1: molecular weight marker, lane 2: cell pellet from 
expression in BL21(DE3); lane 3: supernatant from expression in BL21(DE3); lane 4: flow 
through from the small Ni affinity column purification; lane 5: wash through from the 
small Ni affinity column purification; lane 6: elution from the small Ni affinity column 
purification. 
2.3.11)    Expression of Fpr-LPETGG-His6 
The plasmid containing the fpr-lpetgg-his6 sequencnce (pLLC155) was transformed into E. 
coli  strain  BL21(DE3)  and  the  resulting  protein  was  small  scale  Ni-affinity 
chromatography.    The purified protein was analysed by 15% SDS-PAGE gel stained with 
Coomassie  blue  (Figure  2.13).    From  previous  reports,
5  immatured  cleavage  was 
observed  from  the  expression  of  Fpr-intein  fusion  proteins.    From  the  SDS-PAGE 
analysis, there was no evidence that Fpr-LPETGG-His6 underwent desired cleavage.    This 
finding further confirmed the cleavage of Fpr-intein fusion was due to the instability of the 
thioester linkage between the two proteins.    In our case, no modification to the peptide 
sequence was done until the enzyme was added.    This had a great advantange in terms of 
DsRed-LPETGG-His6 
(~27 kDa) Lilyan Chan 
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Figure 2.13 SDS-PAGE analysis of Fpr-LPETGG-His6 expression. 15% SDS-PAGE gel 
was stained with Coomassie blue for visulisation.    Lane 1: molecular weight marker, lane 
2: flow through from the small Ni affinity column purification, lane 3: wash through from 
the small Ni affinity column purification, lane 4: elution from the small Ni affinity column 
purification. 
 
A large scale expression (5 L) and purification were carried out and the purified protein 
was stored at -80 ℃ for future use. 
2.3.12)    Protein purification 
The  clear  lysate  extracted  from  large  scale  expression  was  loaded  onto  a  Ni-affinity 
column (50 mL) (Prepared in-house see 5.2.17) which was prequilibrated with washing 
buffer.    The  desired  protein  was  purified  from  other  proteins  in  the  present  of  high 
Fpr-LPETGG-His6 (~30 kDa) Production of proteins 
35 
 
concentration of imidazole (500 mM).    After which the eluted protein fractions were gel 
purified to remove excess imidazole to prevent protein precipitation.    The fractions from 
the gel filtration were analysed by SDS-PAGE. 
2.3.13)    Purification of His6-SrtA 
His6-SrtA  (molecular  weight:  23028)  was  purified  from  clear  lysate  by  Ni-affinity 
chromatography as described above.    The flow through, wash through and elution were 
analysed by SDS-PAGE.    The eluted protein fractions were over 95% pure.    Instead of 
gel filfration, the protein was dialysed overnight to remove excess imidazole.    The final 
concentration of SrtA was 123  M, 2.8 mg/mL, as determined by Bradford assay, and was 




Figure 2.14 SDS-PAGE analysis of the purified protein fractions.    15% gel was stained 
with Coomassie blue.    Lane 1: molecular weight marker, lane 2: supernatant, lane 3: water, 
lane 4: fraction 8, lane  5: fraction 10, lane 6: fraction 12, lane 7: fraction 14, lane 8: 
fraction 16, lane 9: fraction 18, lane 10: fraction 20, lane 11: fraction 22, lane 12: fraction 
24, lane 13: fraction 26, lane 14: fraction 28, lane 15: fraction 30. 
His6-SrtA (~21 kDa) Lilyan Chan 
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2.3.14)    Purification of BFP-LPETGG-His6 
BFP-LPETGG-His6  was  purified  from  clear  lysate  by  Ni-affinity  chromatography  as 
decribed above.    The clear lysate extracted after large scale expression was loaded onto a 
Ni  affinity  column.    The  eluted  fractions  containing  were  collected  and  analysed  by 
SDS-PAGE  (Fig.  2.13).    The  fractions  containing  the  purest  protein  (11  to  21)  were 
pooled  and  concentrated.    To  remove  excess  inidazole,  the  concentrated  protein  was 
loaded onto a S200 gel filtration column.    Collected fractions were again analysed by a 
SDS-PAGE.    Fractions with the purest proteins were pooled and concentrated to a final 




Figure 2.15 SDS-PAGE analysis of the eluted protein fractions from Ni-affinity column.   
15% gel was stained with Coomassie blue.    Lane 1: molecular weight marker, lane 2: 
fraction 1, lane 3: fraction 3, lane 4: fraction 5, lane 5: fraction 7, lane 6: fraction 11, lane 7: 
fraction 13, lane 8: fraction 15, lane 9: fraction 17, lane 10: fraction 19, lane 11: fraction 21, 
lane 12: fraction 23, lane 13: fraction 25, lane 14: fraction 27, lane 15: fraction 29. 
BFP-LPETGG-His6 (~28 
kDa) Production of proteins 
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2.3.15)    Purification of EGFP-LPETGG-His6 
Similar  to  BFP-LPETGG-His6,  EGFP-LPETFF-His6  was  purified  from  clear  lysate  by 
Ni-affinity chromatography.    The eluted protein fractions were analysed by SDS-PAGE 
(Fig. 2.14).    Fractions containing the purest protein (7-19) were pooled and concentrated. 
The green protein solution was loaded onto a S200 gel filtration column to remove excess 
imidazole.    Due  to  the  high  purity  of  the  protein  after  Ni  affinity  purifitcation,  the 
fractions were not analysed by SDS-PAGE after gel filtration.    Fractions with bright green 
colour were pooled together and concentrated to 940  M, as determined by Bradford assay, 




Figure 2.16 SDS-PAGE analysis of the eluted protein fractions from Ni-affinity column.   
15%  gel was stained  with Coomassie blue for  visualisation.  Lane 1: molecular  weight 
marker, lane 2: supernatant from expression in  BL21(DE3), lane 3: fraction 1, lane 4: 
fraction 3, lane 5: fraction5, lane 6: fraction 7, lane 7: fraction 9, lane 8: fraction 11, lane 9: 
fraction 13, lane 10: fraction 15, lane 11: fraction 17, lane 12: fraction 19, lane 13: fraction 
21, lane 14: fraction 23, lane 15: fraction 25. 
EGFP-LPETGG-His6 
(~28 kDa) Lilyan Chan 
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2.3.16)    Purification of DsRed-LPETGG-His6 
After large scale expression, clear lysate containing DsRed-LPETGG-His6 was loaded onto 
a Ni affinity column.    The eluted protein fractions were analysed by SDS-PAGE (Fig. 
2.15).    Fractions  containing  the  purest  protein  (13-22)  were  pooled  and  concentrated.   
The  red  protein  solution  was  loaded  onto  a  S200  gel  filtration  column  for  further 
purification and removing excess imidazole. The fractions were analysed by SDS-PAGE.   
The purest fractions were pooled together and concentrated to 418  M, as termined by 




Figure 2.17 SDS-PAGE analysis of the eluted protein fractions from Ni-affinity column.   
15% gel was stained with Coomassie blue for visualisation.    Lane 1: molecular weight 
marker, lane 2: fraction 1, lane 3: fraction 4, lane 4: fraction 7, lane 5: fraction 10, lane 6: 
fraction 13, lane 7: fraction 16, lane 8: fraction 19, lane 9: fraction 22, lane 10: fraction 25, 
lane 11: fraction 28, lane 12: fraction 30. 
DsRed-LPETGG-His6  (~27 
kDa) Production of proteins 
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2.3.17)    Purification of Fpr-LPETGG-His6 
The clear lysate containing Fpr-LPETFF-His6 extracted after large scale expression was 
loaded onto a Ni affinity column and the protein eluted with an increasing concentration of 
imidazole  (50-500  mM).    The  eluted  protein  fractions  had  a  pale  yellow  colour.  The 
fractions were analysed by SDS-PAGE (Fig. 2.16), and the purest fractions (9 to 11) were 
combined and concentrated.    The concentrated protein was loaded onto a PD10 desalting 
column to remove excess imidazole.    The resulting pale yellow protein solution with a 




Figure 2.18 SDS-PAGE analysis of the eluted protein fractions from Ni-affinity column.   
15% gel was stained with Coomassie blue for visualisation.    Lane 1: molecular weight 
marker, lane 2: fraction 1, lane 3: fraction 2, lane 4: fraction 3, lane 5: fraction 4, lane 6: 
fraction 5, lane 7: fraction 6, lane 8: fraction 7, lane 9: fraction 8, lane 10: fraction 9, lane 
11: fraction 10, lane 12: fraction 11, lane 13: fraction 12, lane 14: fraction 13. 
Fpr-LPETGG-His6 (~30 kDa) Lilyan Chan 
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2.4)    Summary and conclusion 
pLLC064 and pLLC066 were successfully constructed for the expression of His6-SrtA and 
BFP-LPETGG-His6 proteins under the control of isopropyl β-D-1-thiogalactopyranoside 
(IPTG)  inducible  promoter.    Plasmids  pLLC146,  pLLC152  and  pLLC155  were 
constructed  from  pLLC066  for  the  expression  of  EGFP-LPETGG-His6, 
DsRed-LPETGG-His6 and Fpr-LPETGG-His6 proteins.    As pLLC155 was subcloned into 
a pBAD vector, the expression was controlled by an arabinose inducible promoter. 
 
A high expression level was observed in all proteins from the expression plasmid in E. coli 
strain BL21(DE3).    All proteins were successfully purified by Ni-affinity chromatography 
and showed high purity.    The expression of LPETGG-His6 tagged proteins was successful 
as no undesired in situ cleavage between the target proteins and the tag was observed.    All 
proteins were found to be stable at room temperature and were stored at and -80 ℃ in 
storage buffer (50 mM Tris, 150 mM NaCl, pH 8). 
 
The purified proteins were used for solution phase labelling experiments (chapter 3) and 
protein immobilisation experiments (chapter 4).Production of proteins 
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2.5)    Experimental methods 






Primers for srtA (SrtAf and SrtAb), were designed such that the PCR products contained 5’ 
NdeI and 3’ EcoRI restriction sites.    Primers for bfp-lpetgg-his6 (LC01 and SOT015) were 
designed to incorporate 5’ NdeI and 3’ EcoRI restriction sites and also introduce a XhoI 
restriction site before the LPETGG-His6 motif. 
2.5.2)    Assembly of pLLC064: His6-SrtA expression vectors 
srtA from Staphylococcus aureus subsp. genomic DNA (ATCC 35556)was amplified by 
PCR using SrtAf and SrtAb primers.    The stock genomic DNA (1 mg/mL) was diluted 
into 3 different concentrations (0.1 mg/mL, 0.01 mg/mL and 0.001 mg/mL) with deionised 
water.    Two  sets  of  PCR  reactions  were  set  (according  to  chapter  5)  for  each 
concentration of genomic DNA, one with MgSO4 and one without.    The PCR products 
were analysed on a 1.5% agarose gel stained with ethidium bromide.    The PCR products 
were then purified using Wizard
® PCR Prep DNA purification system and the purified 
DNA was digested with the restriction enzymes EcoR I and Nde I overnight at 37 ℃ and 
then analysed on a 1.5% agarose gel.    The pETMCSIII plasmid was digested with EcoR I Lilyan Chan 
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and Nde I overnight at 37 ℃ and analysed on a 1.5% agarose gel. The purified srtA PCR 
product and pETMCSIII backbone were ligated using T4 DNA ligase to generate pLLC064.   
The ligation reaction mixture was transformed into XL1-Blue competent cells and then 
plated in LB agar plate supplemented with ampicilin.    A single colony was isolated and 
used to inoculate 10 mL LB medium plasmid DNA prepared.    Plasmid DNA was analysed 
by restriction digestion and DNA sequencing. 
2.5.3)    Assembly of pLLC066:    BFP-LPETGG-His6     
bfp  was  amplified  by  PCR  from  pKLC065  using  primers  LC01  and  SOT015.    The 
amplified gene was analysed by gel electrophoresis and the 750 bp product was isolated.   
The purified PCR product was digested with EcoRI and NdeI and gel purified.    Plasmid 
pSOT048 (pETMCSI) was digested with NdeI and EcoRI to produce a pETMCSI plasmid 
backbone which was gel purified.    The digested and purified PCR product was ligated 
with the pETMCSI plasmid backbone overnight to generate pLLC066.    The ligation mix 
was transformed into XL1-Blue cells, a single colony was isolated and plasmid DNA was 
prepared.    The plasmid DNA was analysed by sequencing and restriction digestion. 
2.5.4)    Assembly  of  pLLC146,  pLLC152:  EGFP-LPETGG-His6, 
DsRed-LPETGG-His6 
pJS110  (egfp-intein-His6)  and  pLLC066  were  digested  with  NdeI  and  XhoI  enzymes.   
egfp and the LPETGG-His6 backbone were gel purified and ligated to form pLLC146. The 
plasmid was transformed into XL1-Blue competent cells. A colony was picked to prepare 
overnight  cultures  and  the  plasmid  was  extracted  by  miniprep  and  then  analysed  by 
analytical digestion.     
pJKS120 (dsred-arg9-intein) and pLLC066 were digested with NdeI and XhoI enzymes to Production of proteins 
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obtain  the  dsred  and  the  plasmid  backbone.    After  gel  purification  the  two  gragments 
were  ligated  to  form  pLLC152  (dsred-lpetgg-His6).  The  plasmid  was  transformed  into 
XL1-Blue competent cells. A colony was picked to prepare overnight cultures and the 
plasmid  was  extracted  by  miniprep.    The  plasmid  DNA  was  analysed  by  restriction 
digestion. 
2.5.5)    Assembly of pLLC155: Fpr-LPETGG-His6 
pRJW/2960/88  and  pLLC066  plasmid  were  digested  with  PciI  and  XhoI.  fpr  and  the 
plasmid backbone were gel purified and then ligated to form pLLC155. The plasmid was 
transformed into XL1-Blue competent cells. A colony was picked to prepare overnight 
cultures  and  the  plasmid  extracted  by  miniprep.    The  plasmid  DNA  was  analysed  by 
restriction digestion. 
2.5.6)    Expression of target-LPETGG-His6 proteins 
pLLC064,  pLLC066,  pLLC146  and  pLLC152  were  transformed  into  E.  coli  strains 
BL21(DE3).    Target  proteins  were  purified  by  Ni-affinity  chromatography  and  then 
analysed by SDS-PAGE.  When  identification of the expressed fluorescent  protein was 
unclear  colonies  were  picked  and  plated  onto  an  agar  plate  contains  IPTG,  left  in  an 
incubator overnight at 37 ℃ and visualised under UV light. 
2.5.7)    Expression of Fpr-LPETGG-His6 proteins 
pLLC155 was transformed into competent E. coli BL21(DE3).    Protein  expression was 
induced by the addition of 0.1% v/v of 20% arabinose.  Target protein was purified by 
Ni-affinity chromatography and then analysed by SDS-PAGE. Lilyan Chan 
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2.5.8) Large scale expression and purification of SrtA and target-LPETGG-His6 proteins 
Buffer A = 50 mM Tris/HCl pH 8.1 + 500 mM NaCl + 50 mM imidazole 
Buffer B = 50 mM Tris/HCl pH 8.1 + 500 mM NaCl + 500 mM imidazole 
Buffer C = 50 mM Tris/HCl pH 8.1 + 500 mM NaCl 
 
a) Ni affinity chromatography 
His6-SrtA was expressed on a large scale (15 L culture) from pLLC064 in BL21 (DE3).  
Cell pellet was lysed and the cleared lysate applied to a pre-equilibrated Ni affinity column 
(50 mL column volume, flow rate = 5 mL / min, washed with 150 mL buffer A, 150 mL 
buffer B and 200 mL buffer A).  Once loading was completed, the column was washed with 
200 mL buffer A.  Protein was eluted at 5 mL / min, over a gradient of buffer B from 0 – 
100% over 600 mL, 12 mL fractions were collected.  A sample was taken out from each 
fraction  and  analysed  with  Bradford  assay  to  detect  the  protein  concentration  in  each 
fraction.  Fractions with proteins were assessed by SDS-PAGE (15% gel).  Fractions were 
combined and concentrated by ultrafiltration (10 kDa MW cut off filter) to a volume of ~ 5 
mL. 
b) Gel filtration chromatography 
To a pre-equilibrated S-200 gel filtration column (column volume = 600 mL, washed with 
2  L  buffer  C)  was  applied  concentrated  supernatant  from  the  Ni  affinity  purification.   
Protein was eluted at 3 mL / min, collecting fractions with 15 mL fraction size.    Protein 
concentration was assessed by Bradford Assay, fractions with proteins were assessed by 
SDS-PAGE.    Fractions  with  puriest  proteins  were  combined  and  concentrated  by 
ultrafiltration (50 kDa MW cut off filter) to a volume of ~15 mL with a final concentration 
of 123  M.     Production of proteins 
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2.5.8)    Purification of BFP-LPETGG-His6 
a) Ni affinity chromatography 
BFP-LPETGG-His6 was expressed on a large scale (15 L culture) from pLLC066 in BL21 
(DE3).  Cell pellet was lysed and the cleared lysate applied to a pre-equilibrated Ni affinity 
column (50 mL column volume, flow rate = 5 mL / min, washed with 150 mL buffer A, 150 
mL buffer B and 200 mL buffer A).  Once loading was complete, the column was washed 
with 200 mL buffer A.  Protein was eluted at 5 mL / min, over a gradient of buffer B from 0 
– 100% over 600 mL.  12 mL fractions were collected, light fluorescent blue colouration 
was observed.  A sample was taken out from each fraction and analysed with Bradford 
assay to detect the protein concentration in each fraction.  Fractions with proteins were 
assessed  by  SDS-PAGE  (15%  gel).    Fractions  were  combined  and  concentrated  by 
ultrafiltration (10 kDa MW cut off filter) to a volume of ~ 5 mL. 
 
b) Gel filtration chromatography 
Protein was eluted at 3 mL / min, collecting fractions with 15 mL fraction size.    Protein 
concentration was assessed by Bradford Assay, fractions with proteins were assessed by 
SDS-PAGE (15% gel).    Fractions with puriest proteins were combined and concentrated 
by  ultrafiltration  (10  kDa  MW  cut  off  filter)  to  a  volume  of  ~15  mL  with  a  final 
concentration of 930  M with light blue colouration.     
  
Figure 2.19 Absorption and fluorescence emission spectra of BFP.
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affinity column (50 mL column volume, flow rate = 5 mL / min, washed with 150 mL 
buffer  A,  150  mL  buffer  B  and  200  mL  buffer  A).    Once  loading  was  complete,  the 
column was washed with 200 mL buffer A.    Protein was eluted at 5 mL / min, over a 
gradient of buffer B from 0 – 100% over 600 mL, 12 mL fractions were collected.    A 
sample was taken out from each fraction and analysed with Bradford assay to detect the 
protein  concentration  in  each  fraction.    Fractions  with  proteins  were  assessed  by 
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b) Gel filtration chromatography 
Protein was eluted at 3 mL / min, collecting fractions with 15 mL fraction size.    Protein 
concentration was assessed by Bradford Assay, fractions with proteins were assessed by 
SDS-PAGE (15% gel).    Fractions with puriest proteins were combined and concentrated 
by  ultrafiltration  (10  kDa  MW  cut  off  filter)  to  a  volume  of  ~15  mL  with  a  final 
concentration of 940  M with bright green colouration.     
 
 
Figure 2.20 Absorption and fluorescence emission spectra of EGFP. 
2.5.10)    Purification of DsRed-LPETGG-His6 
a) Ni affinity chromatography 
His6-SrtA was overexpressed on a large scale (15 L culture) from pLLC152 in BL21 (DE3).   
Cell pellet was lysed and the cleared lysate applied to a pre-equilibrated Ni affinity column 
(50 mL column volume, flow rate = 5 mL / min, washed with 150 mL buffer A, 150 mL 
buffer B and 200 mL buffer A).    Once loading was complete, the column was washed 
with 200 mL buffer A.    Protein was eluted at 5 mL / min, over a gradient of buffer B from 
0 – 100% over 600 mL, 12 mL fractions were collected.    A sample was taken out from 
each fraction and analysed with Bradford assay to detect the protein concentration in each 
fraction.    Fractions  with  proteins  were  assessed  by  SDS-PAGE  (15%  gel).    Fractions Lilyan Chan 
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were combined and concentrated by ultrafiltration (10 kDa MW cut off filter) to a volume 
of ~5 mL. 
 
b) Gel filtration chromatography 
Protein was eluted at 3 mL / min, collecting fractions with 15 mL fraction size.    Protein 
concentration was assessed by Bradford Assay, fractions with proteins were assessed by 
SDS-PAGE (15% gel).    Fractions with puriest proteins were combined and concentrated 
by  ultrafiltration  (50  kDa  MW  cut  off  filter)  to  a  volume  of  ~15  mL  with  a  final 
concentration of 418  M with bright red colouration.     
 
 
Figure 2.21 Absorption and fluorescence emission spectra of DsRED. 
2.5.11)    Purification of Fpr-LPETGG-His6 
a) Ni affinity chromatography 
Fpr-LPETGG-His6 was overexpressed on a large scale (15 L culture) from pLLC155 in 
BL21 (DE3).    Cell pellet was lysed and the cleared lysate applied to a pre-equilibrated Ni 
affinity column (50 mL column volume, flow rate = 5 mL / min, washed with 150 mL 
buffer  A,  150  mL  buffer  B  and  200  mL  buffer  A).    Once  loading  was  complete,  the 
column was washed with 200 mL buffer A.    Protein was eluted at 5 mL / min, over a Production of proteins 
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gradient of buffer B from 0 – 100% over 600 mL, yellow colouration was observed, 12 mL 
fractions were collected.    A sample was taken out from each fraction and analysed with 
Bradford  assay  to  detect  the  protein  concentration  in  each  fraction.    Fractions  with 
proteins  were  assessed  by  SDS-PAGE  (15%  gel).    Fractions  were  combined  and 
concentrated by ultrafiltration (10 kDa MW cut off filter) to a volume of ~5 mL. 
 
b) Gel filtration chromatography 
Protein was eluted at 3 mL / min, collecting fractions with 15 mL fraction size.    Protein 
concentration was assessed by Bradford Assay, fractions with proteins were assessed by 
SDS-PAGE (15% gel).    Fractions with puriest proteins were combined and concentrated 
by  ultrafiltration  (50  kDa  MW  cut  off  filter)  to  a  volume  of  ~15  mL  with  a  final 
concentration of 153  M with pale yellow colouration.     Lilyan Chan 
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Chapter 3:  Solution phase assays 
3.1)    Introduction 
Studying biological interactions at the molecular level is essential in many disciplines.   
Since  biological  molecules  are  often  very  small  in  size,  they  normally  cannot  be  seen 
easily using conventional optical instruments, such as an optical microscope, without being 
labelled with a tag.    These can be a fluorescent label (fluorescent dyes or proteins) or 
even an enzyme that catalyse a visualable reactions.    Other methods include measuring 
the absorbance of the protein of interest at a particular wavelength; measuring the size of 
biological  molecules  by  mass  spectrometry;  solving  the  structure  of  the  of  the 
protein:substrate complex by X-ray crystallography or NMR spectroscopy; detecting the 
emitting radioactivity through the radioactive label, etc.
1           
 
Fluorescence  polarisation  is  another  powerful  technique  for  detecting  molecular 
interactions and conformational changes.    This technique was first described by Perrin in 
1926 and has since been used to study many types of molecular binding.    The principle 
behind  this  is  that  when  a  fluorecenet  molecule  is  excited  with  a  polarised  light,  the 
resulting  fluorescence  is  emitted  in  the  same  polarised  plane  if  the  molecule  remains 
stationary.    In  solution,  if  molecules  tumble  and  roate  during  the  excited  state,  the 
fluorescent light is therefore emitteed in a different plane from the incident light.    The rate 
of rotation and tumbling is inversely proportional to the size of the molecule, so that small 
molecules rotate faster than larger ones.    By measuring the emitted fluorescence light in Solution phase assays 
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vertical  and  horizontal  planes,  we  can  estimate  the  size  of  the  molecules.    Real-time 
fluorescence polarisation measurement can even detect the binding or dissociation of two 
or more molecules (Figure 3.1).
2-4   
 
 
Figure 3.1 Schematic diagram of fluorescence polarisation.    (a) When a large fluorescent 
molecule is excited with a plane polarised light, little movement occurs and as a result the 
emitted fluorescence light is highly polarised. (b) When a small fluorescent molecule is 
excited, however, the rotation is more rapid and therefore the emitted fluorescence is less 
polarised. 
3.1.1) FRET 
Another  fluorescence-based  technique  for  monitoring  molecular  interactions,
5,6 
conformational  changes  within  a  molecule,
7-9  and  protein  complex  formation
10  is 
Fluorescence  resonance  enery  transfer  (FRET).    Although  FRET  was  discovered  by 
Forster as early as in 1948
11 it was not popular until 1970s.
12 




and the other act as an acceptor (Figure 3.2).    The efficiency of FRET depends on three 
main factors, the first is the distance between the acceptor and the donor, which normally 
should be between 10 – 100 Å.
12    Secondly, it depends on the spectral overlap between 
the  donors  emission  spectrum  and  the  acceptors  excitation  spectrum,  and  finally  the 





Figure 3.2 Schematic diagram of FRET.    a) When the donor (blue molecule) and acceptor 
molecules  (red  molecule)  are  separated,  the  green  fluorophore  (donar)  emits  green 
fluorescence  in  a  normal  way.    b)  When  the  donor  are  in  close  approximity,  the 
fluorescence light emitted from the green fluorophore is used to excite the red fluorophore, 
resulting in an increase of red fluorescence from the acceptor molecule. 
A vast number of fluorophores have been used as a FRET pair.    The notable pairs are Solution phase assays 
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fluorescent proteins: cyan fluorescence protein (CFP)/ yellow fluorescence protein (YFP) 
and BFP/GFP.
13    Fluorescent proteins such as GFP can be expressed in different cells and 
is highly fluorescent.
13    It can easily be fused with another protein to produce a fusion and 
retain  its  functionality.    The  gene  of  GFP  can  be  mutated  to  form  different  kinds  of 
fluorescent proteins with different spectral properties which can be used as donors and 
acceptors of FRET.
13-19    This provides a better way to investigate biological mechanism 
and physiological functions of cells.
20-25    Different researchers used FRET to to study the 
interaction between different molecules, for example: between the CD38, contains an ADP 
ribosylcyclase  domain  that  mediates  intracellular  Ca
2+  signaling  by  the  production  of 
cyclic ADP-ribose (cADPR), and lipid raft component ganglioside M(1).
26-34 
3.1.2) Fluorescent labelling of proteins and DNA 
Most proteins are not fluorescent in their nature.    The need to understand the dynamic 
behavior of the non-fluorescent proteins, organelles and cell, has lead to the development 
of methods to fluorescently label biological molecules, including proteins, DNA and RNA.   
 
One of the methods to label proteins is to express fluorescent protein fusion tags. It works 
by inserting the gene that encodes the fluorescent protein next to the target gene sequence.   
After  protein  expression,  the  desired  protein  is  fused  with  the  fluorescent  protein  tag.   
However,  the  product  of  this  fusion  is  large.  For  example,  ECFP-venus,  has  a  overall 
molecular weight of 55 kDa, which is almost three times bigger than the original protein.   
This could decrease the mobility of the proteins.     
 
Another common method to label proteins in solution is the use of synthetic fluorescent 
dyes,  such  as  the  amine-reactive  label  fluorescein  isothiocyante  (FITC).      FITC  has  a 




forms a very stable thiourea bond with the free primary amines on the target biomolecule.   
However, FITC reacts with any free amine available and so the labelling reaction is non- 
specific and uncontrollable.
35    Nonetheless, this fluorescent dye is very easy to use and 
many labelled protein examples can be found in the literature.
36-41     
 
 
Figure 3.3 Molecular structure of fluorescein-5-isothiocyanate. 
 
Intein mediated labelling is another method to label proteins,
42-44 peptides.
45    However, 
the  expression  of  target-intein  fusion  proteins  was  proved  to  be  difficult,  as  the  intein 
domain of the fusion protein can be easily cleaved non-specifically.
46, 47 
 
By using the SrtA system, we aim to develop a new and specific method to fluorescently 
label proteins under a mild condition.    Our next goal was to ligate a range of proteins with 
different substrates, including fluorecein derivaties and other biological molecules. 
   Solution phase assays 
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3.2)    Results and Discussion 
3.2.1)    Assay for Sortase A 
With all the proteins expressed and purified in Chapter 2, the activity of SrtA was analysed 




Figure 3.4 Ligation of BFP-LPETGG-His6 to glycine using SrtA, (1) BFP-LPETGG-His6 
protein, (2) glycine, (3) ligation product BFP-LPETG. 
 
BFP-LPETGG-His6 was incubated with the glycine substrates in the present of SrtA in 
assay buffer.    The reaction was left overnight in the dark at room temperature.    Aliquotes 
were taken at different time points and then loaded onto a pre-eqilibrated Ni-affinity spin 
column.    During  the  ligation  reaction  the  His6  tag  on  the  C-terminus  of 
BFP-LPETGG-His6  was  removed,  therefore  losing  the  ability  to  bind  to  the  affinity 
column.    The flow through from the spin Ni column was collected and transferred to a 
96-well plate for fluorescence analysis using a microplate reader.    Figure 3.5 shows a 
kinetic diagram of the SrtA mediated ligation.    With increasing time, the concentration of 
product increased, leading to an increase in the fluorescent intensity of the flow through 
from the Ni-column.    Two different negative controls were used, one without SrtA and the 







































Negative control (without Sortase)
 
 
Figure 3.5 Fluorescence intensity of Ni column flow through of each assay and fitted to a 
ligand binding one site saturation curve. 
 
From the graph above it shows that diglycine and tetraglycine were the best substrates, as 
they  produced  the  highest  increase  of  fluorescent  intensity  with  a  similar  rate.    With 
glycine as the substrate, the reaction was very slow and close to the two negative controls. 
This suggested that mono-glycine was a poor substrate for the SrtA systemin solution.    In 
the negative control where no substrate was added, an increase in fluorescent intensity was 
also  observed.    A  sample  from  this  reaction  was  taken  and  analysed  by  HPLC  (See 
appendix A).    The results indicated that the BFP-LPET-SrtA intermediate was hydrolysed 
by water, forming BFP-LPET-OH.    As this hydrolysed product lost the His6 tag from the 
C-terminus, the protein failed to bind to the affinity column which results in an increase in 
fluorescent intensity in the flow-through. Solution phase assays 
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3.2.2)  Labelling  of  BFP-LPETGG-His6  with  fluorescein  labelled 
oligoglycine 
After successfully conjugating tagged BFP with different oligoglycines using our noval 
SrtA  system,  our  next  goal  was  to  fluorescently  label  proteins.    We  investigated  the 
labelling  of  BFP-LPETGG-His6  with  different  fluorescein  derivaties  at  different  time 
points.     
 
Three  different  fluorescein-labelled  glycines  were  selected  as  substrates  for  the  SrtA 
labelling  system:  diglycine-fluorescein  (GGF),  triglycine-fluorescein  (GGGF)  and 
tetraglycine-fluorescein (GGGGF).    Tagged target protein (50 µM) was incubated with 
the substrate (500 µM) and SrtA (100 nM) in assay buffer (50 mM Tris, 100 mM NaCl, 5 
mM  CaCl2,  pH  7.5)  at  room  temperature  (CaCl2  was  added  to  the  reaction  was  some 
research suggest that it could increase the reaction rate).    Aliquots containing the protein 
sample were withdrawn at different time points, denatured at 95 °C for 10 min and then 
analysed by SDS-PAGE.   
 
Figure 3.6 shows the fluorescence image (lower image, no staining) and brightfield image 
(upper  panel,  stained  with  Coomassie  blue)  of  the  15%  SDS-PAGE  gel.    Since  the 
fluorescent protein was denatured at high temperature, the matured chromophore was no 
longer in the correct orientation and lost its fluorescence properties.    This can be seen 
from lane 2-4 on the fluorescence and brightfield image.    Over a course of 16 h, all three 
fluorescein-labelled substrated were conjugated to the target proteins.   
 





Figure 3.6 SDS-PAGE analysis of labelling BFP-LPETGG-His6 with different fluorescein 
labelled glycines using the SrtA system.    Top image: Coomassie blue stained brightfield 
image. Lower image: fluorescence images (illuminated by transilluminator, λ = 302 nm, no 
staining).    In both cases: lane 1: protein marker, lane 2 -4: GGF, GGGF and GGGGF 
labelling sample at 0 hour, lane 5-7: GGF, GGGF and GGGGF labelling sample at 1 hour, 
lane 8-10: GGF, GGGF and GGGGF labelling sample at 2 hour, lane 11-13: GGF, GGGF 
and GGGGF labelling sample at 4 hour, lane 14-16: GGF, GGGF and GGGGF labelling 
sample at 6 hour, lane 17-19: GGF, GGGF and GGGGF labelling sample at 16 hour. 
   Solution phase assays 
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The fluorescent intensity from the gel shown above was measured by ImageJ (version 1.42) 
and the corresponding kinetic curves are represented in Figure 3.7. 
Time (Hour)



































Figure 3.7 Labelling of BFP-LPETGG-His6 with fluorescein labelled oligoglycine.    The 
points were fitted to a ligand binding one site saturation curve.    The mean fluorescent 
intensity of each band from figure 3.2 under UV light was measured by ImageJ. 
 
From the graph shown above, all selected substrates showed good labelling efficiency, as 
they  yielded  high  amount  of  labelled  protein  at  the  end  of  the  reaction.    Suprisingly, 
unlikely previous analysis where reaction kinetics were monitored by a plate reader, all the 
substrates showed similar reaction kinetics.    This could be due to the fact that SDS-PAGE 
analysis is not as sensitive as the plate reader.    Although there were some random bands 
below  the  labelled  products,  which  might  due  to  the  degradation  of  proteins  with  a 
LPETGG motif and results in the labelling of degradated protein, the quantity of the bands 




3.2.3)    Labelling of EGFP-LPETGG-His6 with different concentrations 
of fluorescein labelled diglycine 
Our  next  goal  was  to  optimise  the  concentration  of  fluorescein-labelled  oligoglycine 
substrate used in the reaction.    EGFP-LPETGG-His6 and GGF were used for this labelling 
experiment.    Similar to the previous kinetic experiment, the tagged protein (50 µM) was 
incubated with increasing concentration of GGF (0 µM - 1 mM) in the present of SrtA (150 
nM) in assay buffer.    After 16 h, the samples were denatured at 95 ℃ for 10 min, and then 
analysed  by  SDS-PAGE.    Similar  to  BFP,  the  fluorescent  protein  was  unfolded  after 
denaturation and therefore lost the fluorescence properties, as see from lane 2 in Figure 
3.8.   
 
             
Figure  3.8  SDS-PAGE  analysed  of  the  fluorescent  labelling  reaction  of 
EGFP-LPETGG-His6 with increasing concentration of GGF using the SrtA system.    On 
the  left:  15%  gel  brightfield  image  stained  with  Coomassie  blue;  on  the  right:   
fluorescence image of the same gel before staining (illuminated by transilluminator, λ = Solution phase assays 
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302 nm).    In each case: lane 1: protein marker, lane 2: 0  M GGF, lane 3: 1  M GGF, lane 
4: 10  M GGF, lane 5: 50  M GGF, lane 6: 100  M GGF, lane 7: 250  M GGF, lane 8: 
500  M GGF, lane 9: 750  M GGF, lane 10: 1 mM GGF. 
[Fluorescein labelled diglycine] (µ µ µ µM)






































Figure 3.9 Labelling of EGFP-LPETGG-His6 with different concentrations of fluorescein 
labelled diglycine.    The mean fluorescent intensity of each band from figure 3.8 under 
UV light was measured by ImageJ and fit curve to ligand binding one site saturation. 
 
The  graph  above  shows  that  with  increasing  concentration  of  GGF  substrate,  the 
fluorescent  intensity  of  the  product  band  increased.    The  minimum  concentration  of 
fluorescein labelled diglycine needed for a reasonable amount of product was about 50  M.   
The optimized concentration of substrate was determined to be 150  M   
 




concentrations,  BFP-LPETGG-His6  was  labelled  with  the  substrate  at  0  µM  –  25  µM.   
The reaction was monitored by FRET at 37 ℃ over 16 h. 
 
[fluorescein labelled diglycine] (µM)

































Figure 3.10 Initial rate of fluorescent intensity measurement at 518 nm of BFP FRET 
assay with different GGF concentrations and fitted to a linear line. 
 
From  the  graph  above  shown  the  initial  rate  of  the  labelling  reaction  increased  as  a 
function of substrate concentration.      This finding confirmed previous observation where 
the labelling reaction roughly followed a one-site saturation binding profile. 
 
   Solution phase assays 
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3.2.4)    Labelling  of  BFP-LPETGG-His6  with  fluorescein  labelled 
diglycine using different concentrations of SrtA 
We were also interested in studying the minium amount of SrtA needed for the labelling 
reaction.    Similar to the previous experiments, target protein (50 µM) and substrate (GGF, 
10 µM) were incubated with increasing concentration of SrtA (0 nM – 1000 nM) in assay 
buffer overnight.    Samples were denatured at 95 ℃ for 10 min and then analysed by 




Figure  3.11  SDS-PAGE  analysis  of  the  SrtA-mediated  protein  labelling  of 
BFP-LPETGG-His6 with GGF in the present of increasing concentration of SrtA for 16 
hours. On the left is Coomassie blue stained brightfield image; on the right is fluorescence 
image before staining (illuminated by transilluminator, λ = 302 nm).    In each case: lane 1: 
protein marker, lane 2: 0 nM SrtA, lane 3: 1 nM SrtA, lane 4: 10 nM SrtA, lane 5: 50 nM 
SrtA, lane 6: 100 nM SrtA, lane 7: 250 nM SrtA, lane 8: 500 nM SrtA, lane 9: 750 nM 





The images above shown the brightfield image (left, stained with Coomassie blue) and 
fluorescence  image  (right,  no  staining)  of  the  15%  SDS-PAGE  gel.    With  increasing 
concentration  of  SrtA  in  the  reaction  the  amount  of  labelled  target  protein  increased.   
Apart from the target proteins there were a small amount of other proteins labelled with the 
fluorescent substrate.    These could be the truncated proteins and target protein dimers.   
The quantity of these impurities, when compare with the major project, were neglectable.   
The  fluorescent  intensity  of  the  gel  was  analysed  by  ImageJ  (version  1.42)  and  a 
saturation-binding curve was plotted. 
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Figure  3.12  Labelling  of  BFP-LPETGG-His6  with  fluorescein  labelled  diglycine  using 
different  concentrations  of  SrtA.    The  mean  fluorescent  intensity  of  each  band  from 
Figure 3.11 under UV light was measured by ImageJ and the graph was fitted to a ligand 
binding one site saturation curve. Solution phase assays 
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From  the  saturation-binding  curve  shown  above,  it  was  clear  that  10  nM  of  SrtA  was 
enough  to  start  to  catalyse  the  labeling  reaction.    The  amount  of  labelled  products 
increased as a function of [SrtA] until the reaction reached saturation at ~200 nM.   
 
3.2.5) Labelling of different proteins with fluorescein labelled diglycine 
By using the optimised ligation conditions, we attempted to label different proteins using 
the  SrtA  system.    BFP-,  EGFP-,  DsRed-,  Tus-  (prepared  by  H.  Cross)  and 
Fpr-LPETGG-His6 were selected to be labelled with GGF.    In the panel of target proteins, 
BFP, EGFP and DsRed had similar protein structures.    They are known to be robust under 
a wide range of conditions and have been used for a number of labelling technologies.   
Fpr and Tus, on the other hand, have more delicate protein structures.    Previously, Wood 
et al. attempted to label Fpr with fluorecein derivatives using the intein labelling method.   
In the first step, a fusion protein of Fpr-intein had to be expressed.    This was proved to be 
difficult  since  the  thioester  linkage  between  Fpr  and  intein  was  easily  hydrolysed  in 
aqueous environment.    Tus is a DNA-binding protein which recognises the ter sequence. 
It was our interest to study the labelling effiency of these potenitaly challenging proteins 
using our novel system. 
 
Target proteins (50 µM), substrate (10 µM) and SrtA (100 nM) were incubated in assay 
buffer  at  r.t.  for  overnight.    SrtA  was  omitted  from  the  reaction  mixtures  to  serve  as 
negative controls.    After which, the reaction mixtures were denatured at 95 ℃ for 10 min 
and then analysed by SDS-PAGE (Figure 3.13) 
 






Figure 3.13 SDS-PAGE analysis of the Srt-A mediated labelling of BFP-, EGFP-, DsRed-, 
Fpr-, and Tus-LPETGG-His6 with GGF.    Left imgae: 15% gel brightfield image (stained 
with Coomassie blue).    Right image: fluorescence image of the same gel before staining 
(illuminated by transilluminator, λ = 302 nm).    On the left, lane 1: protein marker, lane 2: 
BFP ligation reaction, lane3: BFP negative control, lane 4: EGFP ligation reaction, lane 5: 
EGFP negative control, lane 6: DsRed ligation reaction, lane 7: DsRed negative control, 
lane 8: Fpr ligation reaction, lane 9: Fpr negative control, lane 10: Tus ligation reaction, 
lane 11: Tus negative control.    On the right, the same as on the left but without the protein 
marker. 
 
As  expected,  all  fluorescent  proteins  were  labelled  with  GGF  mediated  by  SrtA 
successfully (left image lane 2-7).    Fpr and Tus were also labelled with the fluorescent 
substrate in high yield.    In all cases, in the absence of SrtA no target protein was labelled.   
Interestingly,  SrtA-mediated  labelling  was  found  to  be  highly  specific.    This  was 
demonstrated in the Tus labelling experiment (left image lane 10 and 11) where in the 
present  of  a  relatively  high  amount  of  other  proteins  only  Tus  was  labelled  with  the Solution phase assays 
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fluorescent substrate.    The functionality of the labelled Tus after SrtA reaction will be 
discussed in Chapter 4. 
3.2.6)  DNA  labeling  of  EGFP-LPETGG-His6  with  different 
concentrations of DNA and pH 
We have demonstrated that SrtA could be used for labelling proteins site-specifally with 
relatively small substrates under mild conditions.    We have now turned our interest in 
labelling proteins with other biological molecules, such as DNA, using our system.    This 
potentially could open up opportunity for a number of applications, such as drug delivery.   
In  this  experiment,  we  aimed  to  label  EGFP-LPETGG-His6  with  ter  conjugated  with 
diglycin at either 5’- or 3’- end (ter-GG, a strand of DNA that bind specifically to Tus 
protein). 
 
The pH of the assay buffer (50 mM Tris, 100 mM NaCl, 5 mM CaCl2, pH 7.5) had to be 
optimised for DNA labelling.    At this condition, the protonated amine group of diglycine 
could bind to the ter DNA phosphate backbone by electrostatic interactions, resulting in a 
self-aggregated cluster which might not be recongised by SrtA.    With this in mind, we 
attempted to label our EGFP-LPETGG-His6 (50 µM) with increasing concentrations of 
ter-GG (0  M, 1  M, 10  M, 20  M, 40  M and 60  M) in the present of SrtA (100 nM) at 
either pH 7.5 or 9.    EGFP-His6 was used as negative control.    Without the LPETGG 
motif, ter-GG should not conjugate with the protein in the present of SrtA.         






Figure 3.14 SDS-PAGE analysis of the conjugation of ter-GG with EGFP-LPETGG-His6 
at  pH  7.5  or  9.    Brightfield  image  of  the  15%  gel  was  acquired  after  staining  with 
Commassie blue.    Lane 1: protein marker, lane 2: 0  M at pH 7.5, lane 3: 0  M at pH 9, 
lane 4: 1  M at pH 7.5, lane 5: 1  M at pH 9, lane 6: 10  M at pH 7.5, lane 7: 10  M at pH 
9, lane 8: 20  M at pH 7.5, lane 9: 20  M at pH 9, lane 10: 40  M at pH 7.5, lane 11: 40 
 M at pH 9, lane 12: 60  M at pH 7.5, lane 13: 60  M at pH 9, lane 14: EGFP-His6 at pH 
7.5 and lane 15: EGFP-His6 at pH 9. 
 
Figure 3.14 shows the SDS-PAGE analysis of the conjugation reaction. The unconjugated 
protein (EGFP-LPETGG-His6) had a MW of 29 kDa, whereas the DNA-conjugated protein 
(EGFP-LPETGG-ter)  appeared  at  ~35  kDa.    As  seen  from  the  gel,  the  conjugation 
reaction performed equally well at either pH 7.5 or 9. The conjugating reaction reached 
satuation when ter-GG was ~10 µM.    The reaction was highly specific as demonstrated in 




This experiement proved that SrtA labelling system could be use to label proteins with 
relatively large substrate, such as DNA, under very mild conditions. 
 
3.2.7)    DNA  labeling  of  EGFP-LPETGG-His6  with  different 
concentrations of EGFP-LPETGG-His6 
After optimising the pH of the assay buffer and substrate concentration, our next goal was 
to optimise the target protein concentration.    The substrate ter-GG (10 µM) was incubated 
with increasing concentration of EGFP-LPETGG-His6 (0  M, 1  M, 5  M, 10  M, 20  M, 
50  M, 75  M, 100  M, 150  M, 250  M) in the present of SrtA (100 nM) in assay buffer 
(pH 9) at r.t. overnight.    Afterwhich, the reaction mixture was analysed by SDS-PAGE. 
 






Figure 3.15 SDS-PAGE analysis of the conjugation of ter-GG to increasing concentration 
of EGFP-LPETGG-His6 at r.t. over 16 h.    15% gel was stained with Commassie blue for 
visualisation.    Lane 1: protein marker, lane 2: 0  M; lane 3: 1  M; lane 4: 5  M; lane 5: 
10  M; lane 6: 20  M; lane 7: 50  M; lane 8: 75  M; lane 9: 100  M;, lane 10: 150  M; 
lane 11: 250  M. 
 
Unconjugated EGFP-LPETGG-His6 had a MW of 29 kDa, whereas the DNA-conjugated 
product appeared at~35 kDa.      Despite of the increase in target protein concentration the 
conjuation  reaction  reached  saturation  at  50-75  µM  of  EGFP-LPETGG-His6.    This 
indicated that the yield of the reaction was less than 20%. Solution phase assays 
74 
 
3.2.8)    DNA  labeling  of  EGFP-LPETGG-His6  with  different 
concentrations of SrtA 
To  improve  the  yield  of  the  conjugation  reaction,  we  attempted  to  optimise  the  SrtA 
concentration  in  the  reaction.    Target  protein  (50  µM)  and  ter-GG  (10  µM)  were 
incubated with increasing concentration of Srt A (0 nM, 10 nM, 20 nM, 40 nM, 60 nM, 80 
nM, 100 nM, 150 nM, 200 nM, 250 nM, 500 nM and 1  M) in assay buffer (pH 9) at r.t. 




Figure 3.16 SDS-PAGE analysis of the conjugation of ter-GG to EGFP-LPETGG-His6 
with  increasing  concentration  of  SrtA  at  r.t.  over  16  h.    15％  gel  was  stained  with 
Coomassie blue for visualisation.    Lane 1: protein marker, lane 2: 0 nM; lane 3: 10 nM; 
lane 4: 20 nM; lane 5: 40 nM; lane 6: 60 nM; lane 7: 80 nM; lane 8: 100 nM; lane 9: 150 
nM; lane 10: 200 nM; lane 11: 250 nM; lane 12: 500 nM; and lane 13: 1000 nM. 




The reaction mixtures were analysed by SDS-PAGE and the conjugated product was seen 
at ~35 kDa.    Although the concentration of SrtA was increasing it had little effect in the 
product  concentration.    The  amount  of  product  produced  was  fairly  uniform  when 
60-1000  nM  of  SrtA  was  used.    The  band  appeared  at  ~55  kDa  might  be  due  to  the 
EGFP-LPET-SrtA intermediate.    This suggested the ter-GG substrate did not ligate to the 
target protein efficiently.    From lane 9, a band just below 29 kDa (EGFP-LPETGG-His6) 
could be seen on the gel.    This could be due to the hydrolysed product of the intermediate.     Solution phase assays 
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3.3)    Summary and conclusion 
In  the  past  few  years,  the  potential  use  of  SrtA  in  biotechnology  was  greatly 
underestimated.
48-53    It was not until recently that researchers started to have increasing 
interest  in  using  the  SrtA  system  for  monitoring  protein-protein  interactions,
54  cell 
labelling
55,56 or even anchoring cell surface proteins to cell walls.
57     
 
We have demonstrated the use of SrtA-meidated ligations for labelling target proteins (BFP, 
EGFP,  DsRed,  Tus  and  Fpr)  site-specifcally  with  fluorescein-labelled  oligoglycine 
substrates.
51,58    The  reaction  conditions  for  labelling  target  protein  with  GGF  were 
optimised and showed good labelling yield.    We also attempted the labelling of EGFP 
with a 21 bp diglycine labelled double-stranded ter DNA sequence.    From the labelling 
experiments and SDS-PAGE analysis, we discoverded that ter-GG was a poor substrate for 
SrtA-  labelling  system  in  solution.    The  substrate  was  unable  to  bind  to  the 
EGFP-LPET-SrtA complex, probably due to steric hinderance.    The target protein-SrtA 
complex was eventually hydrolysed in assay environment over time. 




3.4)    Experimental Methods 
3.4.1)    Assay for Sortase 
The reaction mixture contained 10  M of BFP, 10 nM of SrtA, 200 mM diglycine (10  L 
was added to each 1 mL reaction mixture) in assay buffer ( 150 mM NaCl, 50 mM Tris and 
5 mM CaCl2, pH 7.5).    Another set without SrtA was prepared as negative control.    For 
each reaction mixture, 50  L of sample was taken at 0 minute, after which 10 nM of SrtA 
was added to the assay, and the same amount of deionised water was added to the negative 
control.    Both reaction mixtures were incubated at 37 ℃ and samples were taken at the 
following time points, 5, 10, 20, 30, 60, 90, 120 and 240 minutes.    These aliquots were 
immediately applied to a small Ni-NTA column to stop the reaction by separating SrtA and 
other by-products from the ligated proteins.    Both reaction mixtures were left at 37 ℃ 
overnight and a final sample was taken the following day.    The flow through from each 
Ni-NTA column was collected.    As the product is fluorescent, the fluorescence intensity 
was measured by using the florescencene microplate reader (Safire
2, Tecan, Switzerland).. 
 Solution phase assays 
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3.4.2)    Labelling  of  EGFP-LPETGG-His6  with  fluorescein  labelled 
oligoglycine 
Three  set  of  reactions  of  EGFP-LPETGG-His6  ligation  with  fluorescein  labelled 
oligoglycine (GGF, GGGF, GGGGF) were set up.     
 
Reagent  Quantity  Final concentration 
EGFP-LPETGG-His6  13.5  L  50  M 
Fluorescein labelled oligoglycine  31.2  L  500  M 
SrtA  2  L  100 nM 
Assay  buffer  (50  mM  Tris,  150 
mM NaCl, 5 mM CaCl2, pH 7.5) 
Adjust volume to 250  L 
 
Table 3.1 EGFP-LPETGG-His6 with fluorescein labelled oligoglycine reaction mixture. 
 
An aliquote of 20  L from the reaction mixture was taken out at different time points (0 h, 
1 h, 2 h, 4 h, 6 h, and 16 h).    The aliquots were immediately heated up to 96 ℃ for 10 
minutes for denaturation and stored at – 80 ℃ for storage.    Once the last sample was 
taken and heated, the samples were then analysed with SDS-PAGE gel. 




3.4.3)    Labelling of EGFP-LPETGG-His6 with different concentrations 
of fluorescein labelled diglycine   
Different concentrations of fluorescein labelled diglycine (GGF) (0  M, 1  M, 10  M, 50 
 M,  100   M,  250   M,  500   M,  750   M  and  1  mM)  was  used  to  ligate  to 
EGFP-LPETGG-His6.    The  reaction  mixtures  were  incubated  at  room  temperature 
overnight in the dark.     
 
Reagent  Final concentration   
EGFP-LPETGG-His6  10  M   
GGF  Indicated above 
SrtA  100 nM   
Assay  buffer  (50  mM  Tris,  150 
mM NaCl, 5 mM CaCl2, pH 7.5) 
Adjust volume to 50  L 
 
Table  3.2  Reaction  mixture  of  EGFP-LPETGG-His6  with  GGF  with  different 
concentrations of GGF. 
 
After which an aliquote of 20  L was withdrawn from the samples and then analysed by 
SDS-PAGE. 
   Solution phase assays 
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3.4.4)    Labelling  of  BFP-LPETGG-His6  with  fluorescein  labelled 
diglycine using different concentrations of SrtA 
Different concentrations of SrtA (0 nM, 1 nM, 10 nM, 50 nM, 100 nM, 250 nM, 500 nM, 
750 nM and 1  M) were used to catalyse the ligation of BFP-LPETGG-His6 with GGF.   
The reaction mixtures were incubated at room temperature overnight in the dark.   
 
Reagent  Final concentration   
BFP-LPETGG-His6  50  M   
GGF  100  M   
SrtA  Indicated above 
Assay  buffer  (50  mM  Tris,  150 
mM NaCl, 5 mM CaCl2, pH 7.5) 
Adjust volume to 200  L 
 
Table 3.3 Reaction mixture of BFP-LPETGG-His6 with GGF with different concentrations 
of SrtA. 
 
After which an aliquote of 20  L was withdrawn from the samples and then analysed by 
SDS-PAGE. 




3.4.5)    Labelling of different proteins with fluorescein labelled diglycine 
using SrtA 
To demonstrate that the SrtA system for fluorescently labelling proteins were mild and 
robust, several proteins (BFP-, EGFP-, DsRed-, Tus-, Fpr-LPETGG-His6) were chosen to 
ligate to GGF.    The reaction mixtures were incubated at room temperature overnight in 
the dark. 
 
Reagent  Final concentration   
Protein  Indicated above 
GGF  20  M   
SrtA  100 nM   
Assay buffer (50 mM Tris, 
150  mM  NaCl,  5  mM 
CaCl2, pH 7.5) 
Adjust volume to 200  L 
 
Table 3.4 Reaction mixture of different proteins with GGF. 
 
After which an aliquote of 20  L was withdrawn from the samples and then analysed by 
SDS-PAGE. 
   Solution phase assays 
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3.4.6)    DNA  labeling  of  EGFP-LPETGG-His6  with  different 
concentrations of DNA and pH 
ter-GG:   
 
The  double-stranded  DNA  ter-GG was  used  as  substrate  to  label  EGFP-LPETGG-His6 
using  the  SrtA  system.    Three  sets  of  reaction  were  set  up:  1)  Reaction  mixture  with 
different concentrations of ter-GG.    2) Reaction mixture with different pH of the buffer.   
3) Reaction mixture with EGFP-His6 as negative control. 
 
Set 1): Reaction mixture with different concentrations of ter-GG: 
 
Different concentrations of ter-GG (0.1 nM, 1 nM, 10 nM, 100 nM, 1  M, 10  M and TBB 
(without  any  DNA))  were  chosen  to  optimise  the  DNA  concentration  for  ligation  to 
EGFP-LPETGG-His6.     
 
Reagent  Final concentration   
ter-GG  Indicated above 
EGFP-LPETGG-His6 
(940 mM) 
50 µM   
SrtA (123  M)  100 nM   
Buffer    (50  mM  Tris,  150 
mM NaCl, 5 mM CaCl2, pH 
9) 
Adjust volume to 200  L 
 




Set 2): Reaction mixture with different pH of the buffer: 
 
Similar to set 1 but using pH 9.0 buffer solution.     
 
Set 3): Reaction mixture with EGFP-His6: 
 
Similar  to  set  1  (pH  7.5)  and  set  2  (pH  9.0)  but  replacing  EGFP-LPETGG-His6  with 
EGFP-His6.     
 
Reagent  Quantity  Final Concentration 
ter-GG (250  M)  16  L  10 µM 
EGFP- His6 (178 mM)  22.5  L  50 µM 
SrtA (123  M)  1.7  L  100 nM 
Buffer    (50  mM  Tris,  150  mM 
NaCl, 5 mM CaCl2) 
160  L 
 
 
Table 3.6 Reaction mixture of DNA labelling of EGFP -His6 with different pH of buffer. 
   Solution phase assays 
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3.4.7)    DNA  labeling  of  EGFP-LPETGG-His6  with  different  Protein 
concentrations 
Different concentrations of EGFP-LPETGG-His6 (0  M, 1  M, 5  M, 10  M, 20  M, 50 
 M, 75  M, 100  M, 150  M, 250  M) were chosen to optimise the labelling reaction.     
 
Reagent  Fincal Concentration   
ter-GG (250  M)  10 µM   
EGFP-LPETGG-His6 (940 mM)  Indicated above 
SrtA (123  M)  100 nM   
Buffer    (50 mM Tris, 150 mM 
NaCl, 5 mM CaCl2, pH 9) 
Adjust volume to 200  L 
 
Table  3.7  Reaction  mixture  of  DNA  labelling  of  EGFP-LPETGG-His6  with  different 
concentrations of EGFP-LPETGG-His6. 




3.4.8)    DNA  labeling  of  EGFP-LPETGG-His6  with  different 
concentrations of SrtA 
To optimized the condition for ligation of DNA to EGFP-LPETGG-His6, different SrtA 
concentrations were used (0 nM, 10 nM, 20 nM, 40 nM, 60 nM, 80 nM, 100 nM, 150 nM, 
200 nM, 250 nM, 500 nM and 1  M). 
 
Reagent  Final Concentration   
ter-GG (250  M)  10 µM   
EGFP-LPETGG-His6 (940 mM)  50 µM   
SrtA (123  M)  Indicated above 
Assay Buffer    (50 mM Tris, 150 
mM NaCl, 5 mM CaCl2, pH 9) 
Adjust volume to 200  L 
 
Table  3.8  Reaction  mixture  of  DNA  labelling  of  EGFP-LPETGG-His6  with  different 
concentrations of SrtA. 
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3.4.9)    Ligation  of  BFP-LPETGG-His6  to  GGF  with  different 
concentrations of fluorescein labelled diglycine 
Different concentrations of GGF (0.7  M, 3.5  M, 7.0  M, 11  M, 14  M, 18  M, 21  M 
and 25  M) were used for optimising the labelleding reaction. 
 
Reagent  Final concentration   
BFP-LPETGG-His6  50  M   
GGF  Indicated above 
SrtA  100 nM   
Assay  Buffer    (50  mM 
Tris, 150 mM NaCl, 5 mM 
CaCl2, pH 9) 
Adjust volume to 200  L 
 
Table  3.9  Reaction  mixture  of  BFP-LPETGG-His6  with  different  concentrations  of 
fluorescein labelled diglycine. 
 
The reaction mixture was mixed in a black 96 well plate with three drops of mineral oil on 
top, and the fluorescence was monitored by plate reader at λex = 395 nm, λem = 518 nm 37 
℃ overnight. 




3.4.10)    Ligation  of  BFP-LPETGG-His6  to  GGF  with  different 
concentrations of SrtA 
Different SrtA concentrations (0 nM, 1 nM, 5 nM, 10 nM, 20 nM, 40 nM, 60 nM, 80 nM 
and 100 nM) were used for optimising the labelling reaction. 
 
Reagent  Final concentration   
BFP-LPETGG-His6  50  M   
GGF  25  M   
SrtA  Indicated above 
Assay  Buffer    (50  mM 
Tris, 150 mM NaCl, 5 mM 
CaCl2, pH 9) 
Adjust volume to 200  L 
 
Table 3.10 Reaction mixture of BFP-LPETGG-His6 with different concentrations of SrtA. 
 
The reaction was mixed in black 96-well plate with three drops of mineral oil on top, and 
the fluorescence monitored by plate reader at 37 ℃ overnight (at λex = 395 nm, λem = 518 
nm). 
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Chapter 4:   Protein  immobilisation  on  solid 
supports and surfaces 
4.1) Introduction 
The immobilisation of proteins onto surfaces is crucial to biological applications such as in 
vitro  diagnostic  and  drug  discovery,
1-5  allowing  researchers  to  monitor  molecular 
interactions,  protein  conformational  dynamics,  protein  expression,  and  protein 
translocation in living cells etc.    In such techniques, the immobilised protein
5,6 must retain 
their functionality or configuration on the surface in order to function properly.    This is an 
active and yet challenging area in research.    Many efforts have been made to develop 
different  immobilisation  techniques.  For  example  in  protein  microarrays,  proteins  are 
routinely immobilised onto glass substrates by a number of methods: adsorption; affinity 
binding; and covalent couplings etc.
7-11 
4.1.1) Adsorption 
In  adsorption,  protein  molecules  are  adsorped  to  the  surface  by  a  combination  of 
hydrophobic, electrostatic and other intramolecular interactions.    Although this method is 
very easy to implement, the protein molecules are not bound to the surface permanently.   
In fact, the molecules are in equilibrium of adsorption and desroption.    Over time the 
protein activity isreduced due to protein unfolding and denaturation. 
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4.1.2) Affinity binding 
Another  popular  technique  for  attaching  proteins  onto  surfaces  is  by  affinity  binding.   
Many systems have been developed, for example the His6-tag/Ni-affinity system.    In this 
example, protein molecules are expressed with a histidine tag (his-tag) at either the N- or 
C-termini.    The  His-tagged  protein  molecules  can  easily  be  captured  by  surfaces 
functionalised with Ni-NTA (similar methodology is routinely used in protein purification 
which was decribed in Chapter 3).     
 
However,  the  binding  between  the  his-tag  and  Ni-NTA  is  not  very  strong  and  can  be 
affected by many chemicals,
12 for example, DTT, SDS and EDTA.    Another very popular 
approach  is  the  biotin/(strept)avidin  system.
13-18  In  this  case,  the  surface  of  interest  is 
coated with a layer of avidin (or streptavidin).    Biological molecules functionalised with 
biotin  are  captured  through  the  strongest  non-covalent  linkage.    The  binding  between 
biotin and (strept)avidin is considered to be almost irreversible (Kd ~10
-15 M)
19 and is 
stable under very harsh conditions.
20     
 
 
Figure 4.1 Schematic diagram of an immobilised avidin molecule with one of the four 





Figure 4.2 Structure of biotinylated protein. 
 
This method is often use for DNA-based applications, such as DNA microarrays, where 
synthetic oligonucleotides can easily be modified with biotin.    For proteins, this method 
provides limited solutions mainly due to the limitation of in vitro biotinylation of target 
proteins.
16     
4.1.3) Covalent attachment 
Another popular approach is by covalent attachment.
22-32    For example, glass substrates 
can  be  modified  with  amino  group  functionality  using  (3-Aminopropyl)triethoxysilane 
(APTES).
26    Biological molecules can then be immobilised to the functionalised surface 
using  a  cross-linker  (e.g.  glutaraldehyde)  or  coupling  reagens  such  as 
N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide (EDC).




Figure 4.3 Protein ligation to GMA beads using EDC coupling. 




Figure 4.4 Mechanism of EDC-mediated protein coupling. 
 
Although  not  as  easy  to  implement  as  other  methods,  covalent  attachment  ensures  the 
biological  molecules  are  permenantly  immobilised  onto  the  surface  substrate.    The 
reaction conditions can be fine tuned for each application in order to reach the optimal 
loading level.    There are still a number of disadvantages.    For instance, employing EDC 
as a coupling reagent would result in covalent linkage between any carboxylic acids and 
free  amines.    This  means  the  immobilisation  is  not  site-specific  and  so  the  protein 
molecules are attached to the surface in random orientations.    The use of toxic chemicals, 
such as EDC and glutaralhyde, also means a properly equipeed environment is needed for 
carrying out the chemical reactions. 
4.1.4) Application of micron-sized beads 
Other  than  planar surfaces,  the  immobilization  of  proteins  has  been  extended  to 
three-dimensional  particles,  for  example,  glycidyl  methacrylate  (GMA),
22-26  glass 
beads
27,28  and  magnetic  beads.
29-32    The  immobilisation  of  biologically  interesting Protein immobilisation on solid supports and surfaces 
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proteins  onto  micron-size  beads  like  glass  and  magnetic  beads  could  provide  a  lot  of 
advantages.    For instance, molecular interactions can be monitored on bead surfaces by 
flow cytometry,
23 and easy separation of immobilised proteins from reaction mixture by 
gravitation or magnetic sepearation.    In biological assays, the use of micron-sized beads 
in suspension arrays increase the surface-to-volumn ratio and thereby reduce the volume 
needed for reactions.
23     
 
With the success of labelling target proteins with a number of substrates by SrtA-mediated 
ligation, we would like to develop novel methods for immobilising proteins to a range of 
surface substrates.    These methods should improve the current immobilisation techniques 
which provide a mild and yet site-specific ligation of proteins onto solid supports. Lilyan Chan 
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4.2)    Results and Discussion 
With the success in fluorescently labelling proteins in solution with the SrtA system, our 
next goal was to explore the field in immobilising proteins onto solid supports.    Three 
solid supports with distinctly different properties were chosen: 1) highly crossed linked 
glycidyl methacrylate polymer beads (GMA beads, 5  m diameter, Bangs Laboratories, IN, 
USA);  2)  porous  gel  matrix  (Affi-Gel  102  resin,  Bio-Rad,  Hertfordshire,  U.K.)  and 
microscope glass coverslips (VWR, Leicestershire, U.K.).     
 
 
Figure 4.5 The modification of GMA beads with Aoc-OH followed by one, two or four 
glycine residues. 
 
As the surface is not recognisable by SrtA, it had to be modified with glycines using the 
EDC  coupling  methods.    For  the  GMA  beads  (modified  by  Joseph  She),  the 
amino-functionalised surface was modified with an Fmoc-protected 8-amino-octanoic acid 
spacer  (Fmoc-Aoc-OH).    After  Fmoc  deprotection,  the  surface  was  functionalised 
sequentially with one, two, or four glycine residues (Figure 4.5) 
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4.2.1)    Ligation  of  EGFP-LPETGG-His6  onto  different  oligoglycine 
labelled GMA beads 
Our  first  target  was  the  immobilization  of  proteins  onto  cross-linked  polymer  beads. 
Glycidyl methacrylate (GMA) beads were modified with one, two, or four glycine residues 
as  described  above.    The  mono-glycine,  di-glycine,  and  tetra-glycine  beads  were 
incubated with EGFP-LPETGG-His6 (85  M) and SrtA (40 nM) in assay buffer (50 mM 
Tris-HCl, 150 mM NaCl, 5 mM CaCl2, pH 7.5).    As negative controls, beads with no 
glycine  coupled  were  incubated  with  SrtA  and  EGFP-LPETGG-His6,  and  tetraglycine 
beads were incubated with EGFP-LPETGG-His6 in the absence of SrtA. 
 
Figure 4.6 Attachment of a target protein to glycine-functionalised solid support using 
SrtA system. 
Samples  were  taken  at  various  time  points  and  the  beads  were  analysed  using  a 
fluorescence-activated cell sorter (FACS, FACSAria, BD, NJ, U.S.A.).    Negative controls 
were amino-functionalised beads or diglycine beads without SrtA. Data were collected on 
1000  events  and  the  mean  of  the  fluorescent  population  plotted.  Error  bars  shows  the 
standard errors in the mean fluorescence and were generally smaller than the data points. 








































Figure 4.7 Kinetic analysis of EGFP-LPETGG-His6 immobilisation on mono-, di-, and 
tetra-glycine functionalised GMA beadsusing the SrtA system. 
 
Figure 4.7 shows the kinetic analysis of the SrtA-mediated protein immobilisation.    GMA 
functionalised  with  tetra-glycine  showed  the  most  rapid  fluorescence  increase  and  the 
highest final fluorescence. Di-glycine beads were nearly as effective as tetra-glycine with 
mono-glycine beads showing slower increase and significantly reduced final fluorescence.   
In  both  negative  controls,  where  the  substrate  beads  were  substituted  with 
amino-functionalised  solid  support  or  SrtA  was  omitted,  there  was  little  background 
reaction, suggesting the non-specific binding of the fluorescent proteins to the bead was 
minimum.    These  observations  were  similar  to  our  previous  labelling  experiments  in 
solution.         
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4.2.2) Ligation of EGFP-LPETGG-His6 and DsRed-LPETGG-His6 on to 
GMA beads 
After successfully immobilised EGFP-LPETGG-His6 onto different functionalised GMA 
beads, our next goal was to attach different fluorescent proteins onto the di-glycine beads 
using the same SrtA system.    As demonstrated from the result above, the di-glycine beads 
exibited similar initial rate as the tetraglycine beads and were easier to produce.    EGFP 
and DsRed were separately immobilised onto di-glycine functionalised GMA beads and 
then mixed.      As for negative control, SrtA was omitted from the reaction mixture (with 
EGFP-LPETGG-His6).    Brightfield  and  fluorescence  micrographs  were  obtained  on  an 





Figure 4.8 Immobilisation of fluorescent proteins to diglycine GMA beads.    Diglycine 
GMA beads were incubated with fluorescent proteins in the presence (C and D) or absence 
of SrtA (A  and  B).    Negative control: EGFP-LPETGG-His6 proteins  without SrtA (A: Lilyan Chan 
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brightfield;  B:  fluorescence  image)  Mixture  of  EGFP-LPETGG-His6  and 
DsRed-LPETGG-His6 ligated GMA beads (C: brightfield; DL fluorescence image) 
Figure  4.8  shows  the  micrographs  of  the  GMA  beads  after  protein  immobilisation 
reactions.    EGFP and DsRed were separately immobilised onto di-glycine functionalised 
GMA beads and then mixed (C: brightfield image; D: fluorescence image).    As seen on 
the fluorescence image, the beads were highly fluorescent.    In the negative control where 
SrtA was omitted from the reaction mixture (with EGFP-LPETGG-His6 only) it showed 
little background reactions (A: brightfield image; D: fluorescence image), suggesting a 
very low amount of target proteins were non-specifically bound to the surface. 
 
4.2.3)    DNA binding to Tus ligated GMA beads 
The major limitation of exisiting immobilisation techniques is that the attached proteins are 
captured in a random orientation and sometimes lost the activity due to protein    unfolding.   
In this experiment, we ought to demonstrate that immobilised protein molecules using the 
SrtA system was functional and accessible to other molecules.    Tus-LPETGG-His6 was 
selected to immobilised onto tetraglycine GMA beads using the standard attaching protocol 





Figure 4.9 Attachment of Tus to functionalised solid support using SrtA system. 
 
Tus is a sequence specific DNA-binding protein that recognises the 21 bp ter sites.
33      In 
order to demonstrate the functionality of the immobilised Tus protein of GMA beads, the 
solid  supports  were  incubated  with  different  proportions  of  fluorescein-labelled  terB 
double-stranded sequence and a 21 bp Cy5-labelled dsDNA sequence unrelated to terB in 
binding buffer (50 mM Tris-HCl, 250 mM KCl, 0.1 mM EDTA, 0.1 mM DTT, pH 9). The 
total DNA concentration (terB plus nonspecific DNA) was 100 nM for all samples.   
 
 
Figure 4.10 Attachment of a target protein to a solid support using SrtA system. 
 
After the DNA binding reaction, the beads were analysed by FACS.    A total of 1000 
beads from each reaction were recorded and the fluorescein and Cy5 fluorescence of each 
bead was measured.    If the Tus is still functionable, the fluorescein labelled ter should be 
able to bind to the Tus specifically while the Cy5 labelled non specific DNA will not bind Lilyan Chan 
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to the Tus.    This will result in a high fluorescent intensity in fluorecein channel and low 
fluorescent intensity in Cy5 channel.    The resulting fluorescence-saturation binding curve 
is shown in Figure 4.11.      Non-specific DNA binding (Cy5) was very low in all cases.   
This  was  in  agreement  with  previous  observation  in  solution  in  250  nM  KCl.
34    The 
binding  between  ter  and  immobilised  Tus  showed  a  concentration-dependent 
single-binding process.    The equilibrium dissociation constant (Kd) was determined to be 
29±8 nM, which was comparable with the values measured by fluorescence anisotropy 
(~15 nM at 37 °C) or Biacore (~1 nM at 25 °C).
34   
[ter] (nM)

































Cy5 fluorescence (non-specific DNA)
 
Figure 4.11 Tus protein ligated to GMA beads is accessible to its cognate DNA ligand (ter). 
The sequence specific DNA-binding protein Tus was ligated to diglycine GMA beads. The 
Tus-labelled beads were incubated with varying proportions of fluorescein labelled ter and 
Cy5 labelled non-specific DNA and the bead fluorescence analysed by FACS. The curve is 
a model fit for a single binding process with a Kd of 29 nM. 
 Protein immobilisation on solid supports and surfaces 
104 
 
This experiment demonstrated that proteins with delicate 3-D structures, like Tus, could be 
immobilised  onto  hard  polymeric  supports  using  the  SrtA  system  while  retaining  the 
protein functionality.    This important finding potentially provides an improved, clean and 
straightforward technique for the exisiting biotechnologies.     
4.2.4)    Assay of Tus-LPETGG-His6 ligated tetraglycine GMA beads with 
different concentrations of DNA 
In addition to the above demonstration, we were eagered to provide futher evidence to 
show the ter DNA sequence was specifically bound to the immobilised Tus on the solid 
support.    Seven different concentrations of flurocein-labelled ter (0 nM (TBB), 0.1 nM, 1 
nM, 10 nM, 100 nM, 1  M, 10  M) were prepared.    The Tus-coated GMA beads were 
washed by resuspending in DNA ligation buffer, centrifuged at 13500 rpm for 1 minute, 
and  the  supernatant  discarded.    The  above  washing  steps  were  repeated  twice.    As  a 
negative  control,  tetraglycine-functionalised  GMA  beads  were  used.    The  GMA  beads 
were incubated with different concentrations of labelled ter at r.t. for 3 h with shaking. 
After which the beads were analysed by FACS and the fluorescent intensity was recored. 


















































Figure  4.12  The  fluorescent  intensity  measured  at  530  nm  as  a  function  of  ter 
concentration with the deduction of back ground fluorescent intensity.     
 
The fluorescence-binding curve shown in Figure 4.12 provided further evidence that the 
ter sequence was binding to the immobilised Tus on GMA in a specific manner.    When 
tetra-glycine  GMA  beads  were  used,  the  amount  of  non-speicifcally  bound  ter  was 
neglectable.    In  the  case  of  Tus-GMA,  the  binding  increased  as  a  function  of  ter 
concentration.   
4.2.5)    Removal of ter from immobilised Tus-GMA. 
Our next attempt was to remove the bound ter sequence from the immobilised Tus on 
GMA.    The samples were washed by resuspended in DNA removal buffer (50 mM Tris, 
0.1 mM EDTA, 250 mM KCl, 0.1 DTT, 1 M MgCl2, pH 7.5) at room temperature for 5 Protein immobilisation on solid supports and surfaces 
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minutes, centrifuged at 13500 rpm for 1 minute, and the supernatant was discarded.    The 
above washing steps were repeated for 3 times.    The fluorescent intensity of the washed 
beads were analysed by FACS at 530 nm. 
 
 















































Figure 4.14 The mean fluorescent intensity at 530 nm of ter-Tus-GMA before and after 1 
M MgCl2 wash. 
 
As shown in Figure 4.14, most of the bound ter DNA sequence was washed away from 
Tus-GMA, as indicated by the dramatic drop of fluorescence to near the background level 
(background: ~7000 A.U.).    This indicated not only the DNA could bind the immobilised Lilyan Chan 
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Tus specifically, but also be released from the surface by treating with 1 M MgCl2 solution.   
However, there was still a significant amount of ter remained on the surface.    Probably 
the washing steps needed optimisation, or the DNA sequence was trapped on the surface. 
 
4.2.6)    Labelling of modified affi gel resin with different proteins 
We have successfully demonstrated the immobilisation of different proteins onto 
functionalised GMA beads using the SrtA system.    In addition, we have also proved that 
this attaching method retained the functionality of the immobilised proteins.    Our next 
goal was to demonstrate protein attachment to other solid supports, such as soft-gel matrix 
like beaded agarose affinity support (Affi-Gel 102 resin, Bio-Rad).    Similar to GMA 
beads, Affi-Gel was modified with oligoglycine by incubating the amino-resin with 
diglycine (0.5 M) and EDC (2.5 mM) for three hours at 50 °C.    The resin was packed into 
a small spin column.    Afterwhich BFP-, EGFP-, and DsRed-LPETGG-His6 were ligated 
to the resin overnight at room temperature using the same SrtA system as decribed above, 






Figure 4.15 Ligation of fluorescent proteins onto affi-gel resin.    Diglycine affi-gel resin 
was incubated with fluorescent proteins with the presence and absence of SrtA.    Images 
were taken under white light (a) and UV light (b), the protein labelled in the tubes were 
(from  left  to  right):  Negative  control  (EGFP-LPETGG-His6  proteins  without  SrtA), 
BFP-LPETGG-His6,  EGFP-LPETGG-His6  and  DsRed-LPETGG-His6,  (c)  oligoglycine 
modified Affi-gel resin were separately labelled with EGFP- and DsRed-LPETGG-His6 
and  mixed.  Fluorescence  images  were  obtained  on  an  Axiovert  200  Fluorescence 
microscope with fluorescein and Cy3 filter sets, combined, and false colored. 
 
After the washing steps, the resin could be clearly seen to be labelled with BFP and EGFP 
(Figure  4.15b,  second  and  third  tube  from  the  left),  whereas  the  negative  control 
(EGFP-LPETGG-His6 without SrtA) showed no fluorescence (Figure 4.15b, first tube from 
the left).    Resin labelled with DsRed showed mimimum fluorescence (Figure 4.15b, right 
tube).    This  was  due  to  the  fact  that  the  fluorecent  protein  was  excited  with  UV 
illumination  which  was  much  lower  than  the  λex.    However,  under  the  fluorescence 
microscope with the correct filter sets the fluorescence was clearly visable (Figure 4.15c). Lilyan Chan 
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4.2.7)    Protein immobilization onto glass surfaces 
Finally, with the success on ligation of proteins to hard- and soft-polymeric beads, we 
extend our interest onto planer surfaces, such as a glass surface, to demonstrate the SrtA 




Figure 4.16 Fluorescent labelling of glass surface using SrtA system. 
 
Clean  glass  coverslips  were  modified  with  2%  triethoxy(aminopropyl)  silane  and 
oligoglycine  was  then  coupled  to  the  amino-modified  surface  as  decrobed  above.   
EGFP-LPETGG-His6  and  SrtA  mixture  was  dripped  onto  the  glass  coverslide  and 
incubated overnight at room temperature.    Afterwhich, the glass surface was cleaned with 
assay  buffer  (50  mM  Tris  150  mM  NaCl,  5  mM  CaCl2,  pH  7.5).    To  remove  excess 
non-specific binding proteins the glass surface was incubated in wash buffer (50 mM Tris 
150  mM  NaCl,  5  mM  CaCl2,  1%  SDS,  pH  7.5)  at  room  temperature  for  1  hour.   
Subsequentlly the surface was washed again with assay buffer before being imaged using a 
fluorescence microscope equipped with fluorescein filter sets. 




Figure  4.17  Glass  surfaces  were  modified  with  triethoxy(aminopropyl)  silane  and 
oligoglycine before incubation with EGFP-LPETGG-His6 and Sortase. The surface was 
washed with assay buffer with 1% SDS and imaged using the fluorescein filter sets on an 
Axiovert 200 microscope. (Top left) no SrtA; (Top right) no glycine modification, (Bottom 
left) with SrtA and glycine modification and imaged using the same exposure settings as 
negative  controls,  (Bottom  right)  same  as  (Bottom  left)  but  with  five-fold  reduced 
exposure time. 
 
In the absence of SrtA or oligoglycine, little fluorescence was observed on the glass slides 
(Figure 4.17, top panel). A high fluorescence was observed for the positive sample where 
SrtA was included on the oligoglycine-modified glass surface. The labeling is continuous 
across the modified surface with spots of higher fluorescence. 
 
To prove that the EGFP-LPETGG-His6 protein ligation on the glass surface was specific, a 
glass slide was modified with a layer of photosensitive layer moulded in a dolphin shape 
(prepared by Dr. M. E. Sanderson).    As the mould was soluble in acetone, a modified 
method for functioning the glass surface with triethoxyl(aminopropyl) silane (APTES) in 
water  was  used.    The  photosensitive  layer  was  then  wet  etched  with  methanol  after  




Figure 4.18 The dolphin
fluorescence images taken from the Axiovert 200 microscope equipeed
filter set.    Part of the glass surface was protected by a layer of photosensitive layer which 
was shaped as the University of Southampton dolphin logo (shown on the right).   
surface  was  modified  with
EGFP-LPETGG-His6
containing 1% SDS. 
 
It  was  clear  from  the  image
highly specific.    Areas on the glass slide previ
layer showed little non
111 
coupling  of  oligoglycine  by  EDC  coupling  method.    The  glass  slide  was  treated  with 
6  and  SrtA.    After  washing,  the  glass  slide  was  imaged 
cope equipped with a FITC filter set. 
The dolphin-pattened fluorescent image was reassembled from a number of 
fluorescence images taken from the Axiovert 200 microscope equipeed
filter set.    Part of the glass surface was protected by a layer of photosensitive layer which 
was shaped as the University of Southampton dolphin logo (shown on the right).   
modified  with  APTES  in  water  and  oligoglycine 
6 and SrtA. The surface was washed with methanol and assay buffer 
 
It  was  clear  from  the  image  above  that  the  SrtA-mediated  protein  immobilisation  was 
highly specific.    Areas on the glass slide previously protected by a layer of photosentive 
layer showed little non-specific binding, whereas other areas were visually distinquishable.
Lilyan Chan 
The  glass  slide  was  treated  with 
and  SrtA.    After  washing,  the  glass  slide  was  imaged  using  a 
   
image was reassembled from a number of 
fluorescence images taken from the Axiovert 200 microscope equipeed with fluorescein 
filter set.    Part of the glass surface was protected by a layer of photosensitive layer which 
was shaped as the University of Southampton dolphin logo (shown on the right).    Glass 
in  water  and  oligoglycine  before  incubating  with 
. The surface was washed with methanol and assay buffer 
mediated  protein  immobilisation  was 
ously protected by a layer of photosentive 




4.3)    Summary and conclusion 
 
There  has  been  a  growing  interest  on  immobilising  proteins  onto  solid  supports.    We 
extended  our  interest  from  fluorescently  labeling  proteins  to  attach  different  proteins 
(fluorescent proteins, Fpr and Tus) onto a range of surfaces (highly cross-linked GMA, soft 
polymeric matrix and glass surface).    The coupling of proteins onto surfaces proved to be 
successful.    Non-specific  binding  of  target  protein  to  these  surfaces  was  undetectable.   
During  the  initial  stage  of  immobilising  proteins  onto  glass  surfaces,  we  expereiced 
difficulty when using a short glycine linker.    This was overcome by elongating the glycine 
chain (oligoglycine) to prevent steric hinderence.    The activity of the immobilised protein 
was also tested.    Tus was coated onto GMA beads and then used for capturing the double 
strainded ter DNA sequence.    From our experiments, the immobilised Tus was highly 
functional.    After extensive washing, the bound double stranded DNA was released from 
the  Tus-coated  solid  support,  potentially  open  up  possibility  of  reusing  protein-coated 
surfaces for biological assays. Lilyan Chan 
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4.4)    Experimental Methods 
4.4.1)    Ligation  of  EGFP-LPETGG-His6  onto  different  oligoglycine 
labelled GMA beads 
GMA  beads  (~25  mg)  were  re-suspended  with  100   L  of  assay  buffer,  and  calcium 
chloride (5mM) was added to the EGFP-LPETGG-His6.    The reaction (20  L) was set up 




Reagent  Quantity 
Beads (~25 mg)  2.24 L 
EGFP-LPETGG-His6 (940 mM)  16.76  L 
Deionised water  1  L 
 
Table 4.1 Reaction mixture of GMA beads with EGFP-LPETGG-His6 without sortase. 





Reagent  Quantity 
Beads (~25 mg)  2.24 L 
EGFP-LPETGG (940 mM)  16.76  L 
Sortase (123  M)  1  L 
Assay  buffer  (50  mM  Tris,  150  mM 
NaCl, 5 mM CaCl2, pH7.5) 
1  L 
 
Table 4.2 Reaction mixture of GMA beads with EGFP-LPETGG-His6 with sortase. 
 
A 2  L sample was taken out as a control for time point 0 minutes.    The sample was 
re-suspended with 50  L of assay buffer, centrifuged at top speed for 1 minute and the 
supernatant was discarded.    The wash step was repeated three times and after the final 
wash, the pellet was re-suspended with 20  L of assay buffer.    After the washes, Sortase 
or deionised water was added to the reactions and a 2  L sample was taken out at the 
following time points: 15 minutes, 30 minutes, 45 minutes, 60 minutes and 90 minutes.   
Each sample taken out was washed and re-suspended following the same washing steps as 
the 0 minute sample.    The sample was re-suspended with FACS solvent in a tube and 
loaded onto the FACS machine to measure the fluorescence intensity at 530/30 nm for 
5000 events. 
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4.4.2)    Tus-LPETGG-His6 protein ligation to tetraglycine coupled GMA 
beads 
An overnight ligation of Tus-LPETGG-His6 protein to tetraglycine coupled GMA beads in 
assay buffer (50 mM Tris, 150 mM NaCl, 5mM CaCl2, pH 7.5) for the DNA binding assay.   




Reagent  Quantity 
Tetraglycine GMA beads  11  L 
Tus-LPETGG-His6 (3.59  M)  103  L 
Sortase  6  L 
Assay buffer (50 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH7.5)  1  L 
 
Table  4.3  Reaction  mixture  of  tetraglycine  GMA  beads  with  Tus-LPETGG-His6  with 
sortase. 
 
The reaction was centrifuged at top speed for 1 minute and washed with DNA ligation 
buffer (50 mM Tris, 0.1 mM EDTA, 250 mM KCl, 0.1 DTT, pH 7.5), repeated 3 times.   
The resin was re-suspended with 20  L assay buffer for storage at 4 ℃. 
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4.4.3)    Preparation of double stranded fluorescein labelled ter 
Fluorescein labelled ter:   
 
Both the fluorescent oligo and the opposite strand of ter (ATDBio, Southampton, U.K.) 
were heated up to 96 ℃ and allowed to cool down to room temperature naturally and yield 
10  M fluorescein labelled double stranded DNA.     
 
Reagent  Quantity 
Fluorescent oligo (39.07  M)  211.16  L 
Opposite strand  75  L 
Tus DNA binding buffer (50 mM Tris, 0.1 mM EDTA, 250 mM 
KCl, 0.1 mM DTT, pH 9) 
463.84  L 
 
Table 4.4 Preparation of fluorescein labelled double stranded DNA 
 
The  double  stranded  fluorescein  labelled  ter  (ter-F)  was  used  to  dilute  into  different 
dilutions using Tus DNA binding buffer (50 mM Tris, 0.1 mM EDTA, 250 mM KCl, 0.1 
mM DTT, pH 9) 
 
4.4.4)    DNA binding to Tus ligated GMA beads 
The DNA solution in DNA ligation buffer (50 mM Tris, 0.1 mM EDTA, 250 mM KCl, 0.1 
DTT, pH 7.5) was loaded onto the Tus-LPETGG-His6 protein ligated tetraglycine GMA Lilyan Chan 
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Reagent  Quantity 
Tus-LPETGG-His6 ligated diglycine affi-gel resin    500  L 
DNA ligation buffer (50 mM Tris, 0.1 mM EDTA, 250 mM KCl, 0.1 
DTT, pH 7.5) 
100  L 
 
Table 4.5 Reaction mixture of Tus-LPETGG-His6 ligated GMA beads with fluorescein 




Reagent  Quantity 
Tus-LPETGG-His6 ligated diglycine affi-gel resin    500  L 
Fluorescein labelled ter  100  L 
 
Table 4.6 Reaction mixture of Tus-LPETGG-His6 ligated GMA beads with fluorescein 
labelled ter. 
 
The reaction was incubated at room temperature for 3 hours, observe it under the UV light 
to see the fluorescent light from the DNA. 
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A mixture of fluorescein labelled DNA (100 nM) with the specific Tus binding sequence 
site  and  Cy5  labelled  non-specific  DNA  (100  nM)  were  prepared,  the  total  DNA 
concentration in the reaction was 100 nM.    The GMA beads was resuspended with DNA 
ligation buffer, spun at top speed with bench centrifuge for 1 minute, repeat twice, the 
GMA beads was resuspended in 100  L DNA binding buffer.    Seven sets of diglycine 
coupled GMA beads were prepared, one for the negative control and one for each mixture 
of DNA.    The DNA was loaded into the beads and incubated at room temperature for 3 
hours with shaking, the beads was centrifuged and resuspended with DNA binding buffer, 
repeat the wash step twice.    The GMA beads samples were then loaded into the FACS 
machine to measure the fluorescent intensity of the beads at 530 nm and 660 nm.       
 
4.4.5)    Binding  of  ter-F  to  Tus  ligated  GMA  beads  with  different 
concentrations of fluorescein labelled ter 
 
The DNA was diluted into different concentrations by mixing with DNA ligation buffer (50 
mM  Tris,  0.1  mM  EDTA,  250  mM  KCl,  0.1  DTT,  pH  7.5),  and  was  loaded  into  the 
Tus-LPETGG-His6 protein ligated tetraglycine GMA beads solution.    The reaction was 
set up as the following for each DNA concentration, otherwise stated: 
 





Reagent  Quantity 
Tetraglycine GMA beads    1 mg 




Table 4.7 Reaction mixture of Tus-LPETGG-His6 ligated GMA beads with fluorescein 




Reagent  Quantity 
Tus-LPETGG-His6 ligated tetraglycine GMA beads  1 mg 
Fluorescein labelled ter 
Adjust volume according 
to the concentration 
 
Table  4.8  Reaction  mixture  of  Tus-LPETGG-His6  ligated  GMA  beads  with  different 
concentrations of fluorescein labelled ter. 
 
The reaction was incubated at room temperature for 3 hours and loaded into the FACS 
machine to measure the fluorescent intensity at 530 nm. 
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4.4.6)    Removal  of  fluorescein  labelled  ter  from  Tus  immobilised  on 
GMA beads 
 
A sample was taken from each assay, the DNA binding buffer was removed and the beads 
was resuspended with DNA removal buffer (50 mM Tris, 0.1 mM EDTA, 250 mM KCl, 
0.1 DTT, 1 M MgCl2, pH 7.5) and incubated at room temperature for 45 minutes.    The 
supernatant was discarded and the beads was resuspended with DNA binding buffer (100 
 L), repeat this step twice.    The resin was loaded into the FACS machine and fluorescent 
intensity was measured at 530 nm. 
 
4.4.7)    Functionalization of affi gel resin 
EDC coupling reaction 
 
Buffer A (23.4 mM immidazole in 50 mL of deionsed water, pH 7) and buffer B      (2.5 
mM EDC in 25 mL of buffer A) was prepared for the coupling reaction.    The affi-gel 
resin (500  L, 17  M loading concentration) was added into 540  L buffer B and 170  M 
of diglycine was added into an eppendorf tube and left for gentle shaking at 50 ℃ for 3 
hours.    Transfer the resin into a spin column and centrifuged at 3500 rpm for 1 minute 
and washed with 700  L assay buffer and spun at 3500 rpm for 1 minute for 5 times.    The 
resin was then re-suspended with 500  L of deionsed water and stored at 4 ℃. 
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4.4.8)    Labelling of modified affi gel resin with different proteins 
Diglycine coupled affi-gel resin (500  L) in 500  L of assay buffer (50 mM Tris-HCl, 150 
mM  NaCl,  5  mM  CaCl2,  pH  7.5),  was  added  to  the  BFP-,  EGFP-  and 
DsRed-LPETGG-His6 protein in a 1.5 mL eppendorf tube.    The reaction was set up as 




Reagent  Quantity 
Diglycine coupled affi-gel resin  500  L 
Assay buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2, pH 7.5)  845  L 
BFP-, EGFP-, DsRed-LPETGG-His6  76.6  L 
Deionised water  4.3  L 
 
Table  4.9  Reaction  mixture  of  ligating  different  proteins  onto  diglycine  affi-gel  resins 
without SrtA. 
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Reactions:   
 
Reagent  Quantity 
Diglycine coupled affi-gel resin  500  L 
Assay buffer  845  L 
BFP-, EGFP-, DsRed-LPETGG-His6  76.6  L 
SrtA  4.3  L 
 
Table 4.10 Reaction mixture of ligating different proteins onto diglycine affi-gel resin. 
 
The reactions were incubated at room temperature for overnight with very gentle shaking.   
It was then washed with 700  L assay buffer and centrifuged at 3500 rpm for 1.5 minutes 
in a spin column and repeated for three times.    The flow through was discarded and the 
resin was re-suspended with 700  L of assay buffer. 
4.4.9)    Activation and functionalization of glass surface 
Activation of glass surface without photo sensitive layer 
 
Before the immobilization of EGFP onto glass cover slide, it has to be activated and couple 
an amine onto the surface.   
 
This method was used for the glass surface without the photo sensitive layer.    The glass 
cover was first wash with dry acetone to remove grease and dirt on the surface and air 
dried.    Then  immerse  the  cleaned  cover  slide  into  the  activation  reagent  (1  part 
3-aminopropyltriethysilane and 49 parts of dry acetone) for 30 seconds.    It is then rinsed 
with dry acetone for 3 times and air dried at room temperature.    The glass slides were the Lilyan Chan 
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stored in 50 mL glass vials and stored in dark at room temperature before use. 
 
b) Activation of glass surface with the photo sensitive layer 
 
This method was used for the glass surface with the photo sensitive layer as the acetone 
from the previous method will dissolves the photo sensitive layer.    Then place the cover 
slide into the Petri dish device with dolphin side up and slowly by drop wise drip the 
activation  reagent  (1%  3-aminopropyltriethysilane  in  deionised  water)  onto  the  glass 
surface just to cover up the dolphin and incubated at room temperature for 20 minutes.    It 
is then rinsed with water for 3 times to remove excess activation reagent and air dried at 
room temperature.     
 
4.4.10)    Functionalization of glass surface 
 
Once the glass surface was activated, both kinds can be functionalized with oigoglycine 
using the same method.    For the SrtA be able to recognize the glycine on the glass surface, 
an overnight EDC coupling of glycine was done on the prepared glass cover slides in a 50 
mL glass vial.    So a long chain of glycine is coupled onto the glass surface, which will 
increase the distance between the glycine for ligation and the glass surface and act as a 
linker.    After  the  overnight  EDC  coupling  reaction,  the  glass  surface  was  immerse  in 
ammonium solution at 60 ℃ for 3 hours to remove excess glycine.    The glass surface 
without the dolphin molding was then washed carefully with deionised water for three 
times to make sure that all the ammonium solution was removed.    The glass surface with 
dolphin molding was first wash with deionised water for three times, followed by wash 
with  methanol  to  remove  the  entire  photo  sensitive  layer.    The  glass  surface  finally Protein immobilisation on solid supports and surfaces 
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washed with deionised water for another three times to remove the methanol.    They were 
then stored in assay buffer (50 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH 7.5) before use. 
 
4.4.11)    EGFP-LPETGG-His6 immobilization onto glass surface 
Four different sets of reaction were prepared, three different sets of negative control (set 1: 
without SrtA, set 2: glass cover slide was not prepared by EDC coupling and with SrtA in 
the reaction mixture and set 3: glass cover slide was not prepared by EDC coupling and 
without SrtA in the reaction mixture) were designed, and one positive reaction.    A 20 mL 
reaction  mixture  was  prepared  as  below  and  poured  into  a  50  mL  glass  vial  with  the 
prepared  glass  cover  slide.    The  glass  vials  were  stored  at  room  temperature  in  dark 
overnight. 
 
Reagent  Quantity  Final concentration 
EGFP-LPETGG-His6  800  L  50 mM 
SrtA  17  L  100 nM 
Ligation buffer (50 mM Tris, 150 mM NaCl, 
5 mM CaCl2, pH 7.5) 
Adjust volume to 20 mL 
 
Table 4.11 Reaction mixture for immobilization EGFP-LPETGG-His6 onto modified glass 
surface. 
 
After the overnight ligation, the glass surface was first cleaned with assay buffer (50 mM 
Tris  150  mM  NaCl,  5  mM  CaCl2,  pH  7.5).    To  remove  excess  non-specific  binding 
proteins the glass surface was incubated in wash buffer (50 mM Tris 150 mM NaCl, 5 mM 
CaCl2, 1% SDS, pH 7.5) at room temperature for 1 hour, and followed by the cleaning with Lilyan Chan 
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assay buffer and imageed using the fluorescein filter set on an Axiovert 200 microscope. 
4.4.12)    EGFP-LPETGG-His6 immobilisation onto glass surface with a 
dolphin mold 
The immobilisation of EGFP-LPETGG-His6 onto glass surface was the same as method 54, 
except the glass surface was placed horizontally in a Petri dish with the dolphin mold side 
up.    The reaction mixture was dripped onto the glass surface covering the dolphin mold 
and left at room temperature overnight in dark.    After overnight incubation, the glass slide 
was washed with ligation buffer  (50 mM Tris,  150 mM NaCl, 5 mM CaCl2, pH 7.5), 
followed by a wash with wash buffer (50 mM Tris, 150 mM NaCl, 5 mM CaCl2, 1% SDS, 
pH 7.5) and with a final wash with ligation buffer before imageed using the fluorescein 
filter set on an Axiovert 200 microscope.Protein immobilisation on solid supports and surfaces 
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Chapter 5:  General Experimental Methods 
5.1)    Materials 
Restriction enzymes were purchased from either New England Biolab or Promega.    T4 
DNA  Ligase,  Wizard
  Plus  Minipreps  DNA  Purification  System,  Wizard
  PCR  Preps 
DNA  Purification  System  and  dNTPs  were  purchased  from  Promega.    Primers  were 
obtained from Sigma Genosys or synthesised at the University of Southampton. Agarose 
was purchased from Melford and low melting point agarose from Sigma. Staphylococcus 
aureus subsp. genomic DNA was obtained from ATCC, LB Medium was made using LB 
Broth  mix  from  Sigma  or  chemicals  from  Oxoid.  Ampicillin,  IPTG  and  DTT  were 
obtained from Melford Laboratories Ltd. Bacteriological Agar was purchased from Sigma. 
Polyacrylamide-bis  polyacrylamide  (30%  w/v,  37:5:1)  was  purchased  from  Amresco. 
Competent cells were obtained from frozen stocks at the University of Southampton.    pH 
measurements were performed using a Mettler Delta 340 pH meter connected to a Mettler 
Toledo Inlab 413 Combination Electrode. 
 
PCR was carried out in an Eppendorf Mastercycler gradient machine. Centrifugation was 
carried out in a Heraeus Contifuge Stratos D-37520 Osterode with either rotor Heraeus 
#3057  for  50  mL  centrifugation  or  Heraeus  #3048  for  plate  centrifugation. 
Microcentrifugation was carried out in an Eppendorf centrifuge 5415D. Gels and buffers 
for  SDS-PAGE  were  prepared  as  described  (Sambrook  and  Russell  2001).  All 
polyacrylamide gels were 15% and run on a Biorad Protein-3 electrophoresis unit, at a General Experimental Methods 
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constant  voltage  (200 V).  Agarose  Gel  electrophoresis  was  carried  out  as  described 
(Sambrook  and  Russell  2001).    Incubation  of  cell  cultures  was  carried  out  in  Infors 
Minitron, Innova™ 4400 or Innova™ 4230.    DNA concentration was determined using 
NanoDrop® ND-1000 spectrophotometer  at a wavelength of 260 nm.    Sonication was 
carried out using Soniprep150.    Sequencing was carried out in Beckman Coulter CEQ 
200 XL machine.    Vacuo was carried out in Büchi rotavapor R-114 and RE 111, with 
Büchi water bath 461 and B-480.    Fermentation was carried out in an Incubator Shaker 
innova4400  (New  Brunswick  Scientific).    Bacterial  plate  cultures  were  grown  in  a 
Economy Incubator Size 2 (Gallenkamp). Samples were centrifuged at 4 °C in a Avanti 
J-25 centrifuge (Beckman) centrifuge. For small volumes (sample less than 1.5 mL), a 
microCentrifugette 4214 (ALC) was used. 
 
Superdex 75 (S-75), Superdex 200 (S-200) and Chelating Fast Flow resins were purchased 
from  Pharmacia.    All  other  chemicals  used  were  of  the  highest  quality  available  and 
purchased from Aldrich, Sigma or Fluka. 
 
Standard  sterile  techniques  were  applied  during  microbiological  experiments.    Growth 
media and heat stable solutions were autoclaved, whilst heat labile solutions (antibiotics, 
IPTG and arabinose) were filter sterilised through 0.22 µm filters. 
 
Growth  media  were  supplemented  with  the  appropriate  antibiotic  at  the  following 
concentrations; ampicillin, 100 µg / mL, kanamycin, 30 µg / mL, streptomycin, 10 µg / mL.   
Protein expression was induced by the addition of arabinose (0.2% w/v) for pBAD derived 




5.2)    General Methods 
5.2.1)    PCR 
PCR reactions (20  L) were set up on ice in sterile 200  L PCR tubes and processed in the 
thermocycler using the conditions below, unless otherwise reported. 
 
  Volume  Concentration 
Total 
Quantity 
Sterile Water  12 µL     
Thermopol buffer (10x)  2 µL     
dNTPs  2 µL  2 mM  10 nmoles 
DNA template  1 µL 
1mg/mL  ,  0.1  mg/mL, 
0.001 mg/mL 
1  mg,  100 
µg, 1 µg 
Forward / Reverse primers  1 µL    Each  4 µM  0.05 nmoles 
Vent polymerase 
(1 in 20 dilution)  1 µL  2.5 U / mL  2.5 U 
 
Table 5.1 PCR general reaction mixture. General Experimental Methods 
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Reactions were carried out in the thermocycler as follows: 
 
1 cycle  30 cycles  1 cycle 
95 ℃, 10 minutes  95 ℃, 30 seconds  72  ℃, 10 minutes 
60  ℃, 12 minutes  50  ℃, 30 seconds  4  ℃, for storage 
  72  ℃, 1 minute   
 
Table 5.2 PCR cycle programme. 
 
PCR products were analysed by agarose gel electrophoresis and purified using Wizard® 
PCR Preps DNA purification system, following the manufacturer’s guidelines. 
 
5.2.2)    Transformation 
Competent cells were purchased or prepared as described in 5.2.6.   
 
Competent cell aliquots (50-100  L) were thawed on ice for 10 minutes before addition of 
a ligation reaction mixtures (10  L) or purified plasmid DNA (1  L) with gentle mixing.   
Reaction mixture were maintained on ice for 30 minutes before being heat shocked in a 
temperature controlled waterbath (42 ℃, 45 seconds).    The cultures were then placed on 
ice and SOC medium added (250  L).    Cultures were then incubated in a shaker for 1 
hour  (37  ℃,  180  rpm),  and  then  spread  onto  agar  plates  containing  the  appropriate 
antibiotic and incubated overnight (37 ℃).    Colonies were processed by minipreps and 




5.2.3)    Minipreps 
Plasmid DNA was isolated using Wizard
® Plus Minipreps DNA Purification System, used 
as  stated  in  manufacturers  instructions.    Sterile  water  was  used  to  elute  the  isolated 
plasmid DNA. 
 
5.2.4)    Restriction enzyme digestion (analytical and preparative) 
Analytical digestion of plasmid DNA (50  L, 50-75 ng /  L) isolated from bacterial culture 
(5 mL) was carried out using the following conditions. 
 
Restriction enzyme digestion reactions of plasmid were set up on ice in sterile 200  L 
tubes.    Reactions were carried out at 37 ℃ overnight using the conditions below, unless 
otherwise reported. 
 
  Volume  Concentration  Total Quantity 
Plasmid  50  L  50 - 75 ng /  L  2.5 – 3.75  g 
Buffer  10  L  10X  1X 
BSA  10  L  1 mg / mL  10  g 
Restriction Enzyme (each)  5  L  10 U /  L  50 U 
Sterile Water  25  L     
 
Table 5.3 Analytical digestion reaction mixture 
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Preparative digestion of plasmid DNA (15  L, 100 - 300 ng /  L):   
 
  Volume  Concentration  Total Quantity 
Plasmid  15  L  100 - 300 ng/ L  1.5 – 4.5  g 
Buffer  2  L  10X  1X 
BSA  2  L  1 mg/mL  2  g 
Restriction Enzyme (each)  0.5  L  10 U/ L  5 U 
 
Table 5.4 Preparative digestion reaction mixture. 
 
Reactions were incubated at 37 ℃ for 1.5 hours with a total volume of 20  L. 
. 
5.2.5)    Purification of digested fragments 
Completed preparative digestion reactions (30  L) were loaded onto a 1% low melting 
point agarose gel.    The desired product was excised from the gel and purified using the 
QIAquick
® Gel Extraction Kit or Wizard
® PCR Preps DNA purification system following 




5.2.6)    Competent cell preparations 
TFB I buffer: 
 
Reagent  Final concentration 
Potassium Acetate (KCOOCH3)  30 mM 
Rubidium Chloride (RuCl2)  100 mM 
Calcium Chloride (CaCl2)  10 mM 
Manganese Chloride (MnCl2)  50 mM 
Glycerol  30 mL 
Deionised water  Adjust volume to 200 mL 
 
Adjust the pH to 5.8 by using CH3COOH, filtered the buffer through 0.22  m membrane 
before storage. 
 
Table 5.5 TFB I buffer mixture. 
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TFB II buffer:  
 
Reagent  Final concentration 
MOPS  10 mM 
CaCl2  75 mM 
RuCl2  10 mM 
Glycerol  15 mL 
Deionised water  Adjust volume to 100 mL 
 
Adjust the pH of the beffer to pH 6.5, filtered the buffer through 0.22  m membrane before 
storage. 
 
Table 5.6 TFB II buffer mixture. 
 
An overnight culture of competent cells with 10 mL of LB medium was prepared and 
incubated at 37 ℃ overnight with shaking.    Every utility for preparing the competent cells, 
eg, pipette tips, eppendorf tubes, pipette and buffers were chilled overnight.    1 mL of the 
overnight culture was added into 100 mL of fresh LB medium and then incubated at 37 ℃ 
with shaking.    When the OD600 of the cell culture reached 0.6, the flask was removed 
from the incubator and placed on ice immediately.    The cell culture was then centrifuged 
at 4000 rpm for 10 minutes at 4 ℃.    The supernatant was discarded and the cell pellet was 
placed on ice immediately.    The pellet was resuspended with 10 mL of chilled TFB I 
buffer and kept on ice for 10 minutes at 4 ℃.    The solution was then centrifuged at 4000 
rpm for 10 minutes at 4 ℃.    The supernatant was discardedand the cell pellet was chilled 
on ice and kept at 4 ℃.    The pellet was resuspended in 1.5 mL of chilled TFB II buffer, 
aliquoted and stored at -80 ℃.  
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5.2.7)    Fluorescent intensity measurement 
The  fluorescent  intensity  of  the  solution  phase  assays  were  analysed  by  plate  reader 
(SaFire
2, Tecan, Switzerland).    For GMA beads, the fluorescent intensity was measured 
by FACS machine (FACSAria, BD) and fluorescence microscope (Zeiss Axiovert 200) and 
for affi-gel resins, glass surface were observed by fluorescence microscope. 
 
5.2.8)    Ligation into an expression vector 
Purified fragments from preparative digestions (vector and fragment) were ligated in three 
different ratios between the insert DNA and the plasmid backbone to a final volume of a 10 




1  2  3 
Insert DNA  6  L  4  L  2  L 
T4 Ligase buffer  1  L  1  L  1  L 
Plasmid backbone  2  L  4  L  6  L 
T4 DNA ligase  1  L  1  L  1  L 
 
Table 5.7 Ligation reaction mixture 
 
Ligation  reactions  were  incubated  overnight  at  4  ℃  and  transformed  into  XL1Blue 
competent cells.    Cultures were then incubated in a shaker for 1 hour (37 ℃, 180 rpm), General Experimental Methods 
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and  then  spread  onto  agar  plates  containing  the  appropriate  antibiotic  and  incubated 
overnight (37 ℃).    Colonies were analysed by digestions of minipreps.   
 
5.2.9)    Preparation of plasmid for sequencing 
The concentration of the plasmid was determined by measuring the absorbance at 260 nm, 
where 50  g/mL of dsDNA = 1 absorbance unit. 
 
Plasmid DNA (400 ng) was diluted with sterile deionsed water to a total volume of 11  L.   
The plasmid was incubated at 96 ℃ for 1 minute, after which 1  L of primer and 8  L of 
DTCS Quick start Mix was added.    The reactions were carried out in the thermocycler as 
follows: 
 
30 cycles  1 cycle 
96 ℃, 20 seconds  hold at 4  ℃ 
50  ℃, 20 seconds   
60  ℃, 4 minutes   
 
Table 5.8 Thermocycler cycle for plasmid sequencing 
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After which 5  L of stop solution was added to each reaction. 
 
Reagent  Quantity 
3 M sodium acetate, pH 5.2  2  L 
100 mM EDTA  2  L 
glycogen  1  L 
 
Table 5.9 Stop solution mixture for plasmid sequencing. 
 
The  reaction  mixtures  were  transferred  to  a  96  well  sample  plate,  and  60   L  of  95% 
ethanol  was  added  to  each  sample.    The  sample  plate  was  sealed  with  adhesive  foil, 
mixed thoroughly and centrifuged at 1280 x g for 30 minutes at 4  ℃.     
 
The supernatant was discarded, after which 200  L of 70% ethanol was added to each well.   
The plate was sealed with adhesive foil and then centrifuged at 2900 x g for 15 minutes at 
4  ℃.    The supernatant was discarded carefully from the plate and the washing step was 
repeated wih 200  L of 70% ethanol described above. 
 
The sample plate was placed upside down on a piece of tissue, centrifuged at 124 x g for 
10 seconds.    The supernatant was removed and the sample plate air dried until no ethanol 
remained.    Separation buffer was added to the buffer plate until 2/3 filled.    Then 40  L 
of loading buffer was added to each reaction in the sample plate.    The sample plate was 
sealed with foil and mixed well.    One drop of mineral oil was added to each reaction to 
prevent evaporation.    Both plates were placed into the sequencing machine (CEQ system, 
Beckman Coulter) and analysed according to the manufacturer’s instructions. 
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5.2.10)    Glycerol freeze preperation 
Permanent stocks of plasmid bearing E.  Coli  strains were prepared by adding sterilised 
glycerol (75% v/v, 125  L) to bacterial culture (500  L).  These were stored at -80 °C. 
 
5.2.11)    Protein concentration determination 
Protein concentration was assayed using the method of Bradford 
1.     
 
5.2.12)    15% SDS-PAGE gel 
For  10  mL  of  resolving  gel  solution  (5  mL  per  plate)  the  following  components  were 
mixed in the order as shown in Table 7.7:   
   
Reagent  Quantity 
H2O  2.3 mL 
30% Acrylamide / bis acrylamide  5 mL 
1.5 M Tris/HCl (pH 8.8)  2.5 mL 
10% SDS  0.1 mL 
10% Ammonium Persulphate  0.1 mL 
TEMED  0.004 mL 
 




5 mL of this solution was then added to each plate mould and allowed to set for 45 minutes.   
The top of the gel mixture was covered with a thin layer of water, which was then removed 
carefully.    Once the gel solidified stacking gel was then prepared as in Table 5.11. 
       
 
Reagent  Quantity 
H2O  2.7 mL 
30% Acrylamide / bis acrylamide  0.67 mL 
1.5 M Tris/HCl (pH 6.8)  0.5 mL 
10% SDS  0.04 mL 
10% Ammonium Persulphate  0.04 mL 
TEMED  0.004 mL 
 
Table 5.11 Stacking gel mixture 
 
This mixture was then directly added on the resolving gel and a Teflon comb was inserted 
into  the  gel  solution.    Teflon  combs  were  removed  once  the  gel  was  set  and  gels 
immediately used or stored at 4 ℃. 
 
Samples were prepared by mixing 20 µL protein sample with 20 µL sample loading buffer 
(Table 7.9), denaturing at 95 ℃ for 5 minutes.    Samples were then loaded to the gel. 
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Reagent  Quantity 
0.2 M Tris/HCl (pH 6.8)  2.5 mL 
DTT  154 mg 
SDS  200 mg 
Bromophenol Blue  10 mg 
Glycerol  1 mL 
Deionised water  Adjust volume to 10 mL 
 
Table 5.12 Sample loading buffer stock solution 
 
Reagent  Quantity 
Tris Base  15.1 g 
Glycine  94 g 
10% SDS solution  50 mL 
Deionised water  Adjust volume to 1000 mL 
 
Table 5.13 SDS-PAGE running buffer (×5 stock solution) 
 
The proteins were separated according to their size by applying voltage at 180 V (~15V/cm) 
in SDS-PAGE running buffer for 45 minutes.    After which gel was stained by Coomassie 
brilliant blue (Table 5.14) and then destained in destain solution (Table 5.15) for overnight.   
The stained gel was visualised under white light.     
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Reagent  Quantity 
Coomassie brilliant blue  2.5 g 
Methanol : water (1 : 1)  90 mL 
Glacial acetic acid  10 mL 
 
Table 5.14 Coomassie brilliant blue protein stain 
 
Reagent  Quantity 
Deionised water  4375 mL 
Methanol : water (1 : 1)  375 mL 
Glacial acetic acid  250 mL 
 
Table 5.15 Destain solution 
 
5.2.13)    Small scale expression experiments 
An overnight starter culture (10 mL) (inoculated from glycerol freeze stock) was used to 
inoculate  LB  medium  (100  mL)  containing  100  µg/mL  of  Ampicillin.    Culture  was 
incubated in a shaker (37 ℃, 180 rpm), and growth monitored by measuring the OD600.   
Cells  were  induced  at  OD600  =  0.6  by  the  addition  of  arabinose  for  pBAD  expression 
vectors  (final  concentration  0.2%)  or  IPTG  (final  concentration  1  mM)  for  the  pET 
expression  vector.    The  cells  were  grown  for  a  further  4  h  before  harvested  by 
centrifugation (8 min, 10,000 rpm).    Cell pellets were resuspended in lysis buffer (750 µL) 
(5.2.15)  and  lysed  by  sonication  (6  ×  3  s  on  /  off).    Cell  debris  was  separated  by General Experimental Methods 
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centrifugation  (13,000  rpm,  10  min)  and  the  supernatant  isolated.    Cell  debris  was 
resuspended  in  lysis  buffer  (100  ×  pellet  volume).    Protein  concentration  was  then 
estimated by Bradford assay.    The protein content of both supernatant and pellet were 
analysed by SDS-PAGE. 
 
5.2.14)    Large Scale Expression Experiments 
An overnight starter culture was used as a 1% innoculum for 4 × 1.25 L LB medium 
(containing appropriate antibiotic).    Cultures were incubated in an orbital shaker (37 ℃, 
180 rpm) and cell growth monitored by OD600.    At OD600 0.6 cells were induced by IPTG 
and  incubated  at  37  ℃.    Cells  were  then  harvested  four  hours  post  induction  by 
centrifugation (JA14 rotor, 10,000 rpm, 10 min, 4 ℃) and stored at -80 ℃. 
 
5.2.15)    Cell Lysis 
The frozen cell pellet was resuspended in 5 × w/v lysis buffer (50 mM Tris/HCl pH 8.1, 0.5 
M NaCl, 10% glycerol).    Lysosyme (final concentration of 0.1 mg/mL) were added, and 
the mixture stirred for 30 minutes.    The mixture was then sonicated (10 × 30 s bursts) 
whilst cooled on ice.    Cell debris was separated by centrifugation (JA14 rotor, 10,000 rpm, 




5.2.16)    Protein  purification:    Fast  Protein  Liquid  Chromatography 
(FPLC) 
All enzyme purifications were performed using a Pharmacia FPLC System.  Buffers were 






Matrix  Use 
Superdex 75  13 
Spherical  composite  of 
cross-linked  agarose  and 
dextran. 
Size  exclusion  seperation  of 




Spherical  composite  of 
cross-linked  agarose  and 
dextran. 
Size  exclusion  seperation  of 





45 - 165 
Highly  cross  linked  6% 
agarose,  derivatised  with 
chelating  iminodiacetic 
acid groups. 
Medium  for  immobilised  metal 
ion affinity chromatography 
 
Table 5.16 Resin types used for protein purification     
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5.2.17)    Small scale expression study / nickel spin column purification 
Cells from a cell culture (25 mL of a 100 mL growth) were harvested by centrifugation, 
resuspended in 1 mL lysis buffer and lysed by sonication (5 × 5s bursts).    Cell debris was 
separated by centrifugation (13,000 rpm, 15 mins). 
 
Nickel spin columns were prepared by adding chelating sepherose (150 µL) (Pharmacia 
chelating sepherose
TM fast flow) to a Quiagen QIAquick spin column, excess buffer was 
removed  by  centrifugation  (3,000  rpm,  1  min).    N.B  all  subsequent  elutions  were  by 
centrifugation (3,000 rpm, 1 min, 4 ℃).    The following protocol was then followed:- 
 
Resin was charged with 0.2 M nickel sulphate (300 µL) and eluted by centrifugation.     
 
The resin was washed with 50 mM Tris/HCl pH 8.1 (700 µL). 
                                                                                                                                         
To bind the His tagged protein, cleared lysate (700 µL) was applied to the column, mixed, 
left  to  stand  for  1  minute  followed  by  centrifugation.    The  flow  through  was  then 
reapplied, left to stand for one minute and eluted (repeated once). 
 
The column was washed twice with 700 µL of 50 mM Tris/HCl buffer pH8.1 containing 50 
mM imidazole and 0.5 M NaCl.    After the final wash, the column was centrifuged once to 
remove excess buffer. 
 
His tagged protein was eluted with Tris/HCl buffer pH 8.1 (50 µL, 50 mM) containing 
imidazole (0.5 M) and NaCl (0.5 M).    This buffer was well mixed with the resin and left  
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to stand for five minutes before elution. 
 
The eluted proteins were analysed by 10% SDS-PAGE (method 12).   
 
5.2.18)    Gel filtration column 
Buffer A: 50 mM Tris, 150 mM NaCl, pH 7.5 
 
Pre-equilibrated the S-200 column with 2 L buffer A overnight at 1 mL/min overnight.     
Concentrated  protein  from  Ni  affinity  column  purification  was  loaded  onto  the 
pre-equilibrated S-200 column to remove immidazole.    Protein was eluted at 3 mL / min, 
collecting fractions with 15 mL fraction size. 
 
5.2.19)    Conditions  for  SDS-PAGE  analysis  of  SrtA  mediated 
fluorescent labelling reactions 
Protein samples (10 µL) were denatured in Gel Loading Buffer (10 µL) for five minutes at 
80  ℃  and  analysed  by  SDS-PAGE  on  15%  gels.  Gels  were  visualised  under  UV 
illumination  and  after  Coomassie  staining  using  a  Syngene  GeneGenius  imager.  The 
images were analysed using GeneTools software (Syngene, Cambridge, UK). 
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5.2.20)   Desalting of protein solutions by NAP-10 column 
The column was washed with 25 mL of buffer (50mM Tris/HCl, pH 8.1, 150 mM NaCl), 
then 1 mL of the protein solution was loaded onto the column.    The column was then 
eluted with 1.5 mL of buffer and the elution was collected. 
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5.3)  References 




Mass spectrometry result for the SrtA assay 
Once we had a working assay, we would like to ensure that correct product was formed.   
We have performed another four assays, 1) first negative control (BFP-LPETGG-His6), 2) 
second negative control (BFP-LPETGG-His6 with water and SrtA), 3) assay with glycine 
(BFP-LPETGG-His6 with glycine and SrtA), 4) assay with diglycine (BFP-LPETGG-His6 
with  diglycine  and  sortase)  and  5)  assay  with  tetraglycine  (BFP-LPETGG-His6  with 
tetraglycine  and  SrtA).    A  sample  was  taken  out  from  each  reaction  after  overnight 
incubation at room temperature and analysed by LC/MS.    Here we show the raw data of 
the HPLC traces of each sample.    From the traces, we could conclude that the product 





Figure A 1 Total ion current trace from LC
 
The expected m/z values
1100.1, 1144.0, 1191.6 and 1243.4.    From the ion current trace, the main peaks observed 
were 953.3, 986.6, 1059.5, 1100.1, 1144.1, 1191.9 and 1243.5 which 
the expected values. 
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151 
His6 sample 
Total ion current trace from LC-MS of BFP-LPETGG-
m/z values of the BFP-LPETGG-His6 were: 953.3, 986.3, 1021.6, 1059.4, 
1100.1, 1144.0, 1191.6 and 1243.4.    From the ion current trace, the main peaks observed 
were 953.3, 986.6, 1059.5, 1100.1, 1144.1, 1191.9 and 1243.5 which 
the expected values.    This proved that the correct BFP product has formed
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-His6.     
: 953.3, 986.3, 1021.6, 1059.4, 
1100.1, 1144.0, 1191.6 and 1243.4.    From the ion current trace, the main peaks observed 
were 953.3, 986.6, 1059.5, 1100.1, 1144.1, 1191.9 and 1243.5 which were very similar to 
correct BFP product has formed.  
b) Deionised Water sample
 
 
Figure A 2 Total ion current trace from LC
second half of the peak at 8.74 minutes
 
The expected m/z values
1106.5, 1152.6, 1202.6, 1257.3 and 1317.1.    From the 
different from the expected peaks, but 
of the BFP were not 
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b) Deionised Water sample 
Total ion current trace from LC-MS of assay with no substrate and the first and 
second half of the peak at 8.74 minutes. 
m/z values of the product BFP-LPET-OH were: 954.0, 988.1, 1024.6, 1064.0, 
1106.5, 1152.6, 1202.6, 1257.3 and 1317.1.    From the LC/MS result, the main peaks were 
different from the expected peaks, but similar to BFP-LPETGG-His
 cleaved.    Some small peaks under the main peaks which has a mass 
Lilyan Chan 
 
MS of assay with no substrate and the first and 
: 954.0, 988.1, 1024.6, 1064.0, 
result, the main peaks were 
His6.    This showed most 
ome small peaks under the main peaks which has a mass  
envelope corresponding to the hydrolysis product, which dedicated that only hydrolysis has 
happened in the deionised water assay.
 
c) Glycine sample 
 
Figure A 3 Total ion 
the first and second half of the peak at 8.58 minutes.
 
The expected m/z values
1066.2, 1108.8, 1154.9, 1205.1 and 1259.9.    Fr
different from the expected peaks, but 
BFP-LPETGG-His6.    This showed that most of the BFP 
peaks under the main peaks which has a mass en
Mass spectrometry result for the 
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envelope corresponding to the hydrolysis product, which dedicated that only hydrolysis has 
happened in the deionised water assay. 
Total ion current trace from LC-MS of assay with glycine as the substrate, and 
the first and second half of the peak at 8.58 minutes. 
m/z values of the glycine product BFP-LPETG were
1066.2, 1108.8, 1154.9, 1205.1 and 1259.9.    From the LC/MS result, the main peaks were 
different from the expected peaks, but similar to deionised water, where the peaks 
.    This showed that most of the BFP were not
peaks under the main peaks which has a mass envelope corresponding to the hydrolysis 
Mass spectrometry result for the SrtA assay 
envelope corresponding to the hydrolysis product, which dedicated that only hydrolysis has 
 
MS of assay with glycine as the substrate, and 
were: 956.0, 990.1, 1026.7, 
result, the main peaks were 
to deionised water, where the peaks were 
were not cleaved.    Some small 
velope corresponding to the hydrolysis  
product so it is the same with the assay with water and showed that only hydrolysis has 
happened in the glycine assay.
 
d) Diglycine sample 
 
 
Figure A 4 Total ion current trace from LC
 
The  expected  m/z  values
992.1,  1026.7,  1068.4,  1111.1,  1157.3,  1207.6,  1262.4  and  1322.5.    The  main  peaks 
shown in the LC/MS 
1322.2.    So this shows that the diglycine assay worked as the expected peaks were found 
form the trace. 
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product so it is the same with the assay with water and showed that only hydrolysis has 
happened in the glycine assay. 
 
Total ion current trace from LC-MS of assay with diglycine as substrate
m/z  values  of  the  diglycine  assay’s  product  BFP
992.1,  1026.7,  1068.4,  1111.1,  1157.3,  1207.6,  1262.4  and  1322.5.    The  main  peaks 
 result were: 957.9, 911.8, 1028.5, 1068.1, 1157.0, 1207.3, 1262.1 and 
1322.2.    So this shows that the diglycine assay worked as the expected peaks were found 
Lilyan Chan 
product so it is the same with the assay with water and showed that only hydrolysis has 
 
of assay with diglycine as substrate. 
of  the  diglycine  assay’s  product  BFP-LPETGG  were:  958.0, 
992.1,  1026.7,  1068.4,  1111.1,  1157.3,  1207.6,  1262.4  and  1322.5.    The  main  peaks 
1068.1, 1157.0, 1207.3, 1262.1 and 
1322.2.    So this shows that the diglycine assay worked as the expected peaks were found  
e) Tetraglycine sample
 
Figure A 5 Total ion current trace from LC
 
The expected m/z values
996.2, 1033.1, 1072.8, 1115.6, 1162.1, 1212.6, 1267.6 and 1327.9.    The expected peaks 
were shown in the LC/MS
expected peaks were found form the trace.
 
With  all  the  products  being  confirmed  by  the  LC
experiments were considered.    The ligation using 
way to ligate different 
proteins  using  SrtA 
energy transfer (FRET). 
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e) Tetraglycine sample 
Total ion current trace from LC-MS of assay with tetraglycine as substrate
m/z values of the tetraglycine assay product BFP-LPETGGGG 
996.2, 1033.1, 1072.8, 1115.6, 1162.1, 1212.6, 1267.6 and 1327.9.    The expected peaks 
LC/MS result.    So this shows that the diglycine assay worked as the 
expected peaks were found form the trace. 
ucts  being  confirmed  by  the  LC/MS  as  the  correct  product,  further 
considered.    The ligation using SrtA system 
way to ligate different molecules to the protein, so the next goal would be to
  system  and  produce  labelled  proteins  and  fluorescence  res
energy transfer (FRET). 
Mass spectrometry result for the SrtA assay 
 
traglycine as substrate. 
LPETGGGG were: 961.9, 
996.2, 1033.1, 1072.8, 1115.6, 1162.1, 1212.6, 1267.6 and 1327.9.    The expected peaks 
ycine assay worked as the 
MS  as  the  correct  product,  further 
system is a very mild and rapid 
goal would be to label the 
proteins  and  fluorescence  resonance  
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Figure B 2 Plasmid map of pLLC064 (
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Appendix B 
B1) Sequence of His6 tagged Sortase A from S. aureus
Sequence of His6 tagged sortase A from S. aureus. 
Plasmid Maps 
Plasmid map of pLLC064 (his6-srtA). 
S. aureus 
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Figure B 6 Plasmid map of pLLC155 (fpr-lpetgg-his6). 








Figure B 8 Plasmid map of pJS110 (egfp-intein-his6). 









Figure B 10 Plasmid map of pRJW/2960/88 (fpr-intein). 
 